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SOMMARIO 
 
Il presente lavoro è stato suddiviso in due parti: la prima concernente i domini 
STAS, mentre la seconda i domini Myb/SANT. Il fil rouge che unisce le due parti è 
costituito dalla metodica e dagli scopi, ovvero lo studio della struttura e delle 
interazioni di questi domini tramite NMR in soluzione. 
La prima famiglia di domini trattati, gli STAS (Sulphate Transporter and Anti 
Sigma factor antagonist), è stata originariamente classificata sulla base della 
similarità con gli ASA (Anti Sigma factor Antagonist), domini batterici contenuti in 
proteine coinvolte in risposte contro gli stress ambientali e nell’induzione della 
sporulazione. Gli STAS sono presenti in piante, batteri, funghi e animali, in proteine 
con i ruoli più diversi, come sensori di luce, ossigeno, nucleotidi ciclici, trasportatori 
vari, ecc... Presentano una struttura con cinque β-sheets e quattro α-eliche, 
intercalati in maniera irregolare. Le strutture di domini STAS di trasportatori 
attualmente note (Protein Data Bank, Gennaio 2013) sono cinque: quattro batteriche, 
una di mammifero, nessuna di vegetale. L’unica struttura nota di mammifero 
corrisponde allo STAS di prestina di Rattus norvegicus, mancante della Intervening 
Sequence (IVS), una sequenza variabile da proteina a proteina della stessa famiglia: 
uno degli obiettivi consisteva nell’ottenere questo dominio completo. La succitata 
prestina fa parte della famiglia degli SLC26A, trasportatori anionici transmembrana 
con un ruolo nel mantenimento dell’equilibrio elettrolitico a livello degli epiteli. 
Prestina però è un membro anomalo di questa famiglia, in quanto, nei mammiferi, 
non funziona da trasportatore bensì da proteina motore nell’amplificazione cocleare 
del suono. Oltre all’interesse per lo studio del suo dominio completo dello STAS di 
prestina, l’attenzione è stata focalizzata anche su possibili partner di interazione. Uno 
di essi, ipotizzato sulla base sul modello di attivita di un trasportatore di ammonio in 
cui un dominio C-terminale interagisce con un loop citoplasmatico, poteva essere il 
cosiddetto motivo di Saier, costituito da una tripletta di amino acidi ripetuta 
abbastanza conservata. Il costrutto del motivo di Saier è stato modellato sui dati 
strutturali ottenuti sul trasportatore batterico BicA, un modello che si è dimostrato non 
applicabile per prestina, in quanto il costrutto, una volta clonato ed espresso, ha 
mostrato gravi problemi di solubilità in fase di purificazione, già a livello di proteina di 
fusione. Il dominio STAS su cui sono stati concentrati i maggiori sforzi è quello 
appartenente al trasportatore di solfato SULTR1;2 di Arabidopsis thaliana. Questo 
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proteina presenta una intervening sequence di soli 10 aminoacidi e attualmente non 
sono note strutture di STAS vegetali. Dopo una prova preliminare con un costrutto 
del dominio già disponibile in laboratorio, ne sono stati clonati e testati altri cinque 
che differivano tra loro nella lunghezza della prozione N-terminale della sequenza.. 
Non è stato tuttavia possibile ottenere un campione adatto per studi NMR ma è stato 
scelto il costrutto più promettente per ottimizzazione del tampone finale, sul quale 
nuovi tentativi sono in programma. 
La seconda parte del progetto, svolta presso lo Structural Genomics 
Consortium (SGC) di Toronto, Canada, ha riguardato i domini Myb/SANT. Questi 
domini di circa 50 amino acidi presentano entrambi una struttura con tre eliche, dove 
la seconda e la terza elica (quelle più C-terminali) costituiscono un motivo Helix-Turn-
Helix (HTH). Elementi addizionali, come ulteriori eliche o β-hairpins, possono essere 
presenti. Ciò che li differenzia è la distribuzione della carica superficiale: positiva 
sulla terza elica e negativa sulla prima elica per i Myb, invertita per i SANT. I Myb 
sono noti principalmente come domini che legano il DNA con la loro terza elica, 
anche se nuove evidenze dimostrano che la prima elica può interagire con le code 
basiche degli istoni; i SANT invece legano le code degli istoni con la terza elica. Le 
strutture di due domini di questa famiglia sono stati risolti e presentati in questo 
lavoro: la ripetizione R1 del DNA-binding domain della proteina hDmp1 e il dominio 
SANT2 di NCoR2. hDmp1 è un oncosoppressore che contiene un DNA-binding 
domain costituito da tre ripetizioni imperfette: è stata risolta la struttura della 
ripetizione più N-terminale, R1, che ha dimostrato la tipica struttura a tre eliche dei 
Myb e le stesse proprietà elettrostatiche di superficie. Tuttavia, questa porzione del 
dominio non si lega al DNA, di cui sono state testate sequenze note e altre nuove. 
Questo è in accordo con quanto è già noto sui DNA-binding domain di struttura 
simile, dove l’interazione con il DNA riguarda solo le ripetizioni R2 e R3, mentre R1 
sembra avere una funzione accessoria. L’altro dominio risolto è il SANT2 di NCoR2, 
una proteina che agisce da repressore dei recettori nucleari in assenza di ligando. 
Questa proteina possiede due domini SANT: la struttura di quello situato 
nell’estremità più N-terminale è già stata risolta (PDB: 1XC5) e studiata, in particolare 
come partner di interazione dell’enzima istone deacetilasi 3 (HDAC3). Il dominio 
SANT2 ha dimostrato però proprietà peculiari e differenti dai SANT: oltre ad avere 
una lunga elica addizionale all’estremità C-terminale e una zona di conformational 
averaging tra questa elica e quella precedente, presenta proprietà elettrostatiche di 
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superficie tipiche dei Myb, non dei SANT. Non sono note interazioni con il DNA, ma 
con le code istoniche dell’istone H4, con cui sono stati fatti degli esperimenti di 
binding monitorati tramite 15N-HSQC. La regione interessata da questo legame però 
confina con una mutazione che è stata rilevata nel campione NMR in fase di 
assegnazione: è quindi in programma la produzione della proteina wild-type e la 
ripetizione degli esperimenti con le code di H4. 
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ABSTRACT 
 
The present work is divided in two parts: the first one concerns the STAS 
domains, while the second one the Myb/SANT domains. The guiding thread linking 
the two parts is constituted by the method and the aims: these are the study of the 
structure and of the interactions of these domains by means of NMR techniques. 
The first family, the STAS (Sulfate Transporter and Anti-Sigma factor 
antagonist) was originally discovered by similarity with the ASA (Anti Sigma factor 
Antagonist), bacterial domains contained in proteins involved in the environmental 
stress response and in the induction of sporulation. The STAS are present in plants, 
bacteria, fungi and animals, in proteins with different roles, like light/oxygen/cyclic 
nucleotides sensors, transporters of various kinds, etc… They present a structure 
with five β-sheets and four α-helices, interspersed in a irregular way. The STAS 
structures from transporters currently known (Protein Data Bank, January 2013) are 
currently five: four bacterial one, one of mammal, none vegetal. The only mammalian 
structure known corresponds to the STAS of prestin from Rattus norvegicus, missing 
the Intervening Sequence (IVS), a sequence largely variable among the same family 
of proteins: one of the aims was achieving the full domain. The aforementioned 
prestin belongs to the SLC26A family, transmembrane anion transporters with a role 
in maintaining the electrolytic balance in epithelia. However, prestin is an anomalous 
member of this family, since it does not work as a transporter but as the motor protein 
responsible of the cochlear sound amplification. Besides the interest in the study of 
the full STAS domain, the attention was focused also on possible interaction partner. 
One of them, based on the activity model of an ammonium transporter where its C-
terminal domain interacts with a cytoplasmic loop, could have been the so called 
Saier motif, constituted by a repeated amino acid triplet with a certain degree of 
conservation. The construct for the Saier motif was modelled on structural data 
available for the bacterial transporter BicA, a model that demonstrated to be not 
applicable to prestin, since this construct, cloned and expressed, had severe 
problems of solubility during the purification, already as a fusion protein. The STAS 
domain were most of the efforts were focused on was the one belonging to the 
sulfate transporter SULTR1;2 from Arabidopsis thaliana. This domain presents a 10 
amino acid intervening sequence and no STAS structures from plants are currently 
known. After a trial with a construct already available, five new ones were cloned and 
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tested. Anyway, it has not been possible obtaining a NMR sample but the most 
promising construct has been chosen for further attempts to optimize the final NMR 
buffer. 
The second part of this thesis, carried out at the Structural Genomics 
Consortium (SGC) in Toronto, Canada, deals with the Myb/SANT domains. These 50 
amino acid domains present a three helix structure, where the second and the third 
helix (the most C-terminal ones) constitute a Helix-Turn-Helix (HTH) motif. Additional 
elements, such as further helices or β-hairpins, could be present. The difference of 
this domains stays in the distribution of the superficial charge: positive on the third 
helix and negative on first one for the Myb, the opposite for the SANT. The Myb are 
known chiefly as DNA-binding domains with their third helix, even if new evidence 
support that the first helix can interact with the basic histone tails; the SANT instead 
bind the histone tails with their third helix. Two domains of this family were solved 
and presented in this work: the repeat R1 of the DNA-binding domain of hDmp1 and 
the SANT2 domain of NCoR2. hDmp1 is a tumour suppressor protein with a DNA-
binding domain constituted by three imperfect repeats: the structure of the most N-
terminal repeat, R1, was solved, which showed the typical three helix structure and 
the same electrostatic surface properties of the Myb domains. Anyway, this portion of 
the domain does not bind DNA, tested with known and new sequences. This result is 
in agreement with what is known about DNA-binding domains of similar structure, 
where the interaction with DNA concerns only the R2 and R3 repeat, while R1 seems 
to have a secondary function. The other domain solved is the SANT2 of the protein 
NCoR2, a protein acting as nuclear receptor repressor in the absence of ligand. This 
protein has two SANT domains: the structure of the most N-terminal one was already 
solved (PDB. 1XC5) and studied, in particular as interaction partner of the enzyme 
histone deacetylase 3 (HDAC3). Nevertheless, the SANT2 domain has shown 
particular properties: besides a long additional helix at the C-terminal and a region of 
conformational averaging between these helix and the previous one, it presents 
electrostatic surface properties typical of the Myb, not of the SANT domains. No DNA 
interactions are known, but with the H4 histone tails, used for binding experiments 
monitored by 15N-HSQC. However, the concerned region lies in proximity of a 
mutation that was detected in the NMR sample during the assignment: the production 
of the wild-type protein and the repetition of the binding experiments have been 
planned.
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1. INTRODUCTION 
 
1.1 The STAS domain 
 
Gram-positive bacteria, such as Bacillus subtilis, respond to unfavourable 
environment conditions in different ways, depending on the type of stress and on its 
intensity. Severe stress leads the bacteria to turn into quiescent and dehydrated 
forms, the spores. The process leading to the sporulation involves a cascade of 
transduction signals that starts with the sigma factor σF, which leads the bacterial 
RNA polymerase to the transcription of sporulation-specific genes. When its 
inactivation is required, σF is bound to the anti-σ SpoIIAB, which, in turn, is regulated 
by the anti-anti-σ or anti-σ antagonist SpoAA. In this way, the anti-sigma factors 
antagonists activate the bacterial RNA polymerase by inhibiting its anti-sigma factors 
(1). More frequently, when the intensity of the stressful event is lower, like small 
changes in environmental pH, temperature, ethanol, blue light, the effect is the 
activation of another subunit controlling the RNA polymerase, σB, which leads to the 
transcription of the stress genes. This sigma factor is released by RsbU, a 
phosphatase which is controlled by three proteins: RsbR, RsbS and RsbT, 
constituting a complex called the stressosome (2) (3). In both cases, some of the key 
proteins involved contain or exclusively consist in a particular domain called ASA 
(Anti Sigma factor antagonist), of approximately 150 amino acids. In fact, in the 
sporulation process, SpoAA is composed by a single ASA domain, like RsbS, while 
the RsbR is a multidomain protein containing one of these ASA domains (3). 
This domain is not just present in the bacterial proteins as the aforementioned 
anti-sigma factor antagonists of σB and σF: unexpectedly, a significant sequence 
similarity between the ASA and the C-terminal domains of a kind of anion 
transporters present in bacteria, fungi, plants and animals, the SulP family, was 
found and the new domain was called STAS (Sulfate Transport and Anti Sigma 
factors antagonist) (4). Later on, the same domain was discovered also in the 
phototrasduction mechanism in the LOV-STAS domains of the protein YtvA in 
Bacillus subtilis, giving account to the response of σB and the stressosome to the 
blue light (5) (6). 
The structural elements of STAS usually are 4 β-strands and 5 α-helices, with a 
similar folding. However, even if the fold is conserved, the sequence similarity can be 
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low, in particular in the loop between α1 and β3: this segment is also the most 
evident difference with the bacterial ASA, where it is absent. In other organisms, this 
“intervening sequence” (IVS) or “variable loop” can reach up to 150 amino acids and 
it is predicted to be unstructured in solution . In the tract spanning between β3 and 
α2, there is a conserved loop, where no insertion is admitted, probably suggesting 
that this a functionally important region (4). 
The STAS is generally considered as a protein interaction domain, but it covers 
also different functions, such as nucleotidase/nucleotide-binding transduction units in 
sensor proteins, or it is important for the correct membrane targeting and activity of 
the sulphate transporter Sultr1;2 in Arabidopsis thaliana (7). Although little is known 
about STAS activity, it seems that phosphorilation can play a role in its modulation: 
the Ser57 in SpoIIAA is phosphorilated by the protein kinase SpoIIAB and the 
substitution of the equivalent residue (Thr587) in the STAS domain of the Sultr1;2 
abrogates its sulphate transport activity. Interestingly, the phosporilable residues are 
localized in the conserved loop (8). Another possible mechanism of regulation 
involves the interaction of the STAS domain with a cytoplasmatic loop belonging to 
the same protein: this kind of interaction between a cytoplasmic loop and a C-
terminal extention has already been demonstrated for the AMT ammonium 
transporter in Arabidopsis thaliana (9), so it is not excluded that it could occur also in 
the STAS-containing SulP transporters. However, the complete set of functions, 
interactions and regulation of the STAS domains is yet to be defined. In figure 1 
some of the STAS structures solved are reported. 
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Figure 1: (A) rappresentation of the general sequential organization of the STAS domain, from ref. 
(6); (B) solution structure of spoIIAA (10) (PDB: 1AUZ); (C) solution structure of the STAS domain of 
Rv1739c from Mycobacterium tuberculosis (11) (PDB: 2KLN); (D) crystal structure of the STAS 
domain of the prestin (SLC26A5) from Rattus norvegicus, without the intervening sequence (12) (PDB: 
3LLO). 
 
 
 
1.2 The SLC26 transporter family: structure, functions and pathology 
 
The balance of ions in the epithelial tissues is of critical importance in the 
homeostasis: it is fundamental then that the transport system is efficient and that any 
imbalance can be buffered properly (13). The disruption of this equilibrium can lead 
to diseases, such as cystic fibrosis and congenital chloride diarrhoea (14). The 
maintenance of this electrolytic balance is supported by a system of transporters with 
different affinity for various ions: one of this family is the SLC26 transporters, a 
subfamily of the wider SulP (sulfate permease) proteins, encompassing bacteria, 
plants and animals (13). 
A B
C D
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In humans, the SLC26 family has 11 member, with SLC26A10 being considered 
a pseudogene. These transporter can be classified in three groups, based on the 
different transport activity: sulphate transporters (SLC26A1, SLC26A2), coupled Cl-
/HCO3- exchangers (SLC26A3, SLC26A4, SLC26A6) and ion channel (SLC26A7, 
SLC26A9). The transport activity of SLC26A8 and SLC26A11 has not been 
elucidated and SLC26A5 does not seem to work as an anion transporter in mammals 
or has a weak activity (13). The SLC26 transporters differ not only for the activity, but 
also for the tissue distribution and for their involvement in diseases The details about 
each human SLC26 transporter are reported in table 1. 
The SLC26 family members are transmembrane proteins of 700-1000 amino 
acids, sharing a sequence identity of 21-43% and working as dimers (15).The central 
part of the proteins consists in the hydrophobic transmembrane α-helices, where the 
anion binding sites and the pores are localized. The exact number of membrane 
spanning segments is still debated, but most likely there are between 10 and 14 
helices (16). It is also probable that the anion binding sites can be in proximity of 
helices that breaks and turn in the membrane, exposing backbone amide and 
carboxyl groups in a hydrophobic environment (17). The most conserved regions of 
the SLC26 transporters are the transmembrane hydrophobic elices, encompassing 
also the cytosolic N-terminal “sulfate transport” consensus part. A second portion of 
conserved residues is toward the C-terminal end of the transmembrane region and it 
is characterized by the presence of the almost invariant triplet NQE, as observed by 
Saier (18). At the cytosolic C-terminal end there is a STAS domain (16), in some 
transporters followed by a PDZ-binding motif (19). 
STAS functions are not well understood, but evidence supports the speculation 
that it can be a protein-protein interaction domain in the SLC26 transporters. In fact, it 
has been demonstrated that the STAS domain of SLC26A8 can interact with 
MgcRacGAP (20), the STAS domains of  SLC26A3 binds to the R domain of CFTR 
(21) and the mouse Slc26a6 STAS to the carbonic anydrase II (22). 
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Table 1: Features of the member of the SLC26A family in human; adapted from (14). 
 
Gene name 
Protein 
name 
Known 
substrates 
Tissue 
distribution 
Disease 
associations 
Gene 
locus 
GenBank 
accession 
ID 
SLC26A1 Sat-1 
SO42-, 
oxalate, Cl- 
Kidney, liver Unknown 4p16.3 AF297659 
SLC26A2 DTDST SO42-, Cl- 
Multiple 
tissues 
Chondrodysplasias 
5q31-
34 
U14528 
SLC26A3 
DRA, 
CLD 
SO42-, Cl-, 
HCO3-, OH-, 
oxalate 
Intestine, 
pancreas, 
sweat 
glands, 
prostate 
Congenital chloride 
diarrhea 
7q31 L02785 
SLC26A4 Pendrin 
Cl-, HCO3-, I-, 
formate, 
fructose, 
mannose 
Inner ear, 
thyroid, 
kidney, brain 
Pendred syndrome, 
Non-syndromic 
deafness (DFNB4) 
7q31 AF030880 
SLC26A5 Prestin ? 
Outer hair 
cells of 
cochlea 
Non-syndromic 
hearing loss 
7q22 AC005064 
SLC26A6 
CFEX, 
PAT-1 
SO42-, Cl-, 
HCO3-, OH-, 
oxalate, 
formate 
Multiple 
tissues 
Unknown 3p21.3 AF279265 
SLC26A7 None 
SO42-, Cl-, 
oxalate 
Kidney Unknown 8q23 AF331521 
SLC26A8 Tat1 
SO42-, Cl-, 
oxalate 
Brain, sperm Unknown 6p21 AF331522 
SLC26A9 None 
SO42-, Cl-, 
oxalate 
Lung Unknown 
1q31-
32 
AF331525 
(SLC26A10) None Pseudogene Brain Unknown 12q13 NM_133489 
SLC26A11 None SO42- 
Multiple 
tissues 
Unknown 17q25 NM_173626 
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1.3 A divergent SLC26 protein, prestin, is responsible for the cochlear amplification in 
mammals 
 
The sense of hearing is mediated by different organs in the mammalian ear. In 
the organ of Corti, in the cochlea, two kind of cells take part in the hearing: the inner 
hair cells (IHCs) perceive the sound and transmit the sensory information to the 
brain, while the outer hair cells (OHCs) are motile cells, with particular stereocilia 
(hair bundles) whose stimulation by the sound waves triggers the opening and 
closing of ion channels in the membrane (23) (figure 2). The change in the 
membrane potential due to the ions passage has a dramatic effect on the shape of 
OHCs, which are contracted in response to depolarization or elongated because of 
hyperpolarization: this conformational change occurs at microsecond rates, leading 
to a sound amplification of thousand of times (24). Another interesting feature of 
OHC is the “Non Linear Capacitance”, which corresponds to the ability of separating 
charges at the two opposite surfaces of a dielectric (a non conductor) when they are 
maintained at different voltages, but induced in a voltage-dependent way (25). 
At the basis of this change of cell length there is the protein SLC26A5, known 
as prestin. It was identified by subtractive cloning in the search of a protein not 
present in IHCs and that could give account for the electromotility of OHCs: it 
resulted as a 80 KDa transmembrane protein with unique properties (26). Prestin 
shares just a weak transport activity with the SLC26A family (27), but it has the 
special capacity of working as a “motor protein”, coupling the transmembrane voltage 
to the OHC electromotility, without the need of energy supply such as ATP hydrolysis 
(28). It is interesting to note that prestin is still an electrogenic antiporter in non 
mammalian vertebrates such as zebrafish and chicken, where it exchanges oxalate 
or sulfate for chloride with 1:1 stoichiometry but it does not produce any 
electromotility (29). 
The mechanism underlying the capacity of prestin of sensing the “gating 
current” generated by the charge movement is still debated between two theories. 
The first hypothesis considers the intracellular anions as the real voltage sensors of 
prestin and it is called “the partial anion transporter model” (30). In fact, mutagenesis 
experiments concerning substitutions of non conserved charged amino acids in the 
putative membrane domain with other charged or neutral amino acids did not abolish 
the electrical signature of prestin, although in some mutants the non linear 
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capacitance was altered. On the other hand, the removal of Cl- from the cytoplasm 
caused a loss of non linear capacitance, while it was preserved with all the 
monovalent anions tested in patch-clamp experiments (with a relative preference of: 
I-≈Br->NO3->Cl->HCO3->F-). However, the only anions supposed to be present at 
millimolar concentration in the cytoplasm are Cl- and HCO3- and so these are the 
natural candidate as the extrinsic voltage sensors. The proposed mechanism starts 
with the anion binding to a site and its subsequent translocation through the 
membrane by the transmembrane voltage. The direction of the translocation is 
toward the extracellular surface or the cytoplasm in response to hyperpolarization or 
depolarization respectively. This movement of the anion across the membrane has 
an effect on the surface area that triggers a conformational change with 
morphological consequences at the cellular level: the OHC surface area decreases 
and the cell is contracted when the anion is close to the cytoplasmic side, while the 
shift of the anion toward the extracellular surface causes cell elongation due to an 
increase in the cell surface area. 
A different theory about prestin’s mechanism (“the intrinsic voltage sensor 
model”) states that the voltage sensor is not constituted by the intracellular anions, 
but from prestin itself (31). In particular, it was suggested that there is a charged 
portion of prestin that traslocates upon changes of membrane polarization, inducing a 
conformational change in the protein. The purported segment of prestin responsible 
for the anion sensing was mapped by mutagenesis in a putative transmembrane 
helix, in a portion of the protein which shares a high similarity with SLC26A6, the 
closest family member that does not show any voltage sensitivity. According to this 
theory, the anions act as allosteric modulators on prestin’s structure. The figure 3 
illustrates the two different theories. 
To propagate the conformational change of prestin to the OHC, the protein must 
be present in the cell lateral membrane at a high density, up to 10 millions per cell 
(32) and may interact with proteins involved in maintaining the cell structure: as a 
matter of fact, one of its binding partner is the Microtubule-associated Protein 
MAP1S. In particular, the interaction concerns the tract between the heavy and the 
light chain of MAP1S and part of the STAS domain of prestin (the first three β-
strands, the first α-helix and the IVS) (33). 
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Figure 2: Anatomical representation of the cochlea and of its different cellular components (34). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Illustration of the two different theories about prestin electromotricity (31). The depolarization 
of the membrane corresponds to contracted state of prestin, while the hyperpolarization to an 
expansion of the protein. The membrane cycle between hyperpolarization and depolarization is 
caused by the traslocation of a prestin charged portion q in the intrinsic voltage sensor model (IVS) 
(left) or anion-binding site (for Cl- or bicarbonate) in the partial anion-transporter model (PAT) (right). 
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1.4 The sulfate transporter SULTR1;2 and its STAS domain in Arabidopsis thaliana 
 
Sulfur in plants is necessary for the production of compounds like the amino 
acids methionine and cysteine, glutathione, vitamins and cofactors such as thiamine, 
coenzyme A and biotin (35). The first step is the acquisition of sulphur from the soil 
as sulfate (SO42-), followed by the transport through other cell membranes. In the 
cells, the sulphate is then stored in vacuoles or metabolized in chloroplasts and 
plastids. The shift of sulphur from one plant district to an other is controlled by 
sulphate transporters (36) (figure 4). 
The sulfate uptake is carried out by members of the transporter SLC26 family. 
In Arabidopsis thaliana, there are 14 sulfate transporters, 12 of wich containing a 
STAS domain, grouped in 5 categories based on the sequence similarity (37). The 
family members involved in the first step of the sulfur metabolism are two high affinity 
transporters, SULTR1;1 and SULTR1;2, expressed in roots hair and epidermal and 
cortical cells (38). This two transporters present a certain degree of functional and 
spatial distribution overlap but SULTR1;2 is prevalent over SULTR1;1, providing 
around 80% of the sulphate uptake. SULTR1;1 has a lower Km value for the uptake 
of trace amounts of sulphate and it seems to gain more functional importance in case 
of sulphate deprivation, which triggers an increase in its expression, while the 
expression of SULTR1;2, which is expressed constitutively, is just slightly  boosted in 
these conditions (39) (figure 5). They are closely related, with an amino acid 
sequence identity of 69%. 
From the structural point of view, SULTR1;2 is predicted to have 12 
transmembrane helices and the STAS domain is located in its cytosolic C-terminal 
end. STAS seems to have some fundamental roles for SULTR1;2 activity: it is 
important for the localization of the transporter to the plasma membrane and for the 
regulation of its transport activity (7) (8). In particular, the swapping of the STAS 
domain between different transporters affects the kinetic of the transport, suggesting 
that STAS performs transporter-specific tasks (7). Based on comparison with other 
transporters, it is speculated that STAS can do inter- and intra-molecular interactions, 
with proteins, small molecules and cytosolic portions of the transporter itself, 
regulating the transporter activity. For the STAS of SULTR1;2, a direct interaction 
with a enzyme involved in sulfur metabolism, the cysteine synthase (O-acetylserine 
(thiol)lyase or OASTL) was demonstrated with the two hybrid assay (40). The binding 
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has a negative effect on SULTR1;2 activity but positive on OASTL in in vitro 
experiments; OASTL can bind also SULTR1;1 STAS in the two hybrid system 
experiment but their binding has not any influence on OASTL activity (40). 
The STAS domain present also a particular feature in the sequence : a couple 
of adjacent cysteines (Cys645 and Cys 646). The Cys 645 is conserved in many of 
the Arabidopsis sulphate transporters and replaced by a hydrophobic amino acid in 
the other tansporters, while the second cysteine is present only in SULTR1;2, 
substituted by polar amino acids in other sulfate transporters (8). Site directed 
mutagenesis experiments on these two residues demonstrated that they are not 
essential for the sulfate uptake but they are necessary for the optimal activity of 
SULTR1;2 (8). Another interesting residue is also the threonine-587, which 
corresponds to the serine-58 of SpoIIAA, that undergoes phosphorilation: it is not 
clear yet if Thr-587 is phosphorilated too, but its deletion or substitution abrogates 
completely the sulphate uptake by SULTR1;2 (8). 
A better understanding of the mechanism of sulfur uptake by plants can be 
useful in finding solutions for agriculture in sulfur-deficient territories (41) (42) 
 
 
 
Figure 4: Sulfur cycle in Arabidopsis thaliana (36). 
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Figure 5: (A) Activity of SULTR1;1 and SULTR1;2 in normal conditions and (B) under sulfur 
deprivation (43). 
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2. AIMS 
 
During the first part of this PhD, the project concerned the study of selected 
STAS domains with the objectives described in the following. 
 
Achieving the complete structure of the prestin STAS from Rattus norvegicus, 
with IVS 
 
Referring to a previous PhD project, where the structure of an engineered STAS 
domain of prestin from Rattus norvegicus was solved by crystallography and studied 
also by NMR (12), we wanted to go further trying to achieve the full domain structure. 
The crystal structure misses the intervening sequence, originating a general model of 
the mammalian STAS. The consequence of this deletion is a wider angle between α1 
and α2, compared with the STAS of YchM and Rv1739c. 
The interest in the full structure was not only related in obtaining the STAS of 
prestin and not of an engineered prototypical version, but also in achieving a 
structure with the intervening sequence, useful for possible interaction studies, 
specifically for prestin. The role of the IVS is still unknown and it is supposed to be 
unstructured. Currently, pathologic mutations in that region have been detected just 
in pendrin (6).  
 
Obtaining a portion of rat prestin, the Saier domain, as a possible 
intramolecular interaction partner of STAS 
 
The investigation was opened also for possible inter- and intra-molecular 
interaction partners. In particular, a tract of the SLC26A family is conserved and in 
some predictions it is proposed as cytosolic or partially cytosolic (34) (44). This 
protion is called “the Saier motif” and it is characterized by the presence of the triplet 
-NQE- (18). In some transporters, an interaction between a C-terminal domain and a 
cytosolic loop has been demonstrated, as a regulatory mechanism (9). We 
investigated then if the Saier motif could act as cytosolic loop interacting with the 
STAS of the same protein (rat prestin). Since no structure of SLC26A transporter is 
available, we based the design of the construct on the topological studies reported in 
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ref. (45), about the bacterial SulP transporter BicA, where the Saier motif is cytosolic 
(figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Topology of the bicarbonate transporter BicA from Synechoccus PCC7002 (45). The Saier 
motif is circled with a red line. 
 
Obtaining a suitable NMR sample of the STAS domain of SULTR1;2 from 
Arabidopsis thaliana for structure determination 
A STAS domain from the vegetal reign was also considered: the one from the 
sulfate transporter SULTR1;2 form Arabidopsis thaliana. In fact, the majority of the 
STAS structures solved are bacterial for the greatest majority, with one from 
mammals and none from plants. Moreover, this STAS has the IVS, which is not 
present in bacteria and was deleted in the mammal one, but it is relatively short (10 
amino acids, based on the comparison with spoIIAA from Bacillus sphaericus). In the 
case that the small IVS had not a too deleterious effect on NMR spectra (line 
broadening for instance), there could be not  the possibility of solving a full STAS with 
the IVS. 
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3. MATERIAL AND METHODS 
 
3.1 Expression and purification of the STAS domain of prestin from Rattus 
norvegicus with the intervening sequence 
 
100 l of a frozen aliquote of Escherichia coli BL21(DE3) were cultivated in 3 ml 
of LB medium for 5 h and then transferred in 100 ml of minimal medium M9 for an 
overnight culture, at 37°C, 180 rpm. The overnight culture was diluted to 1 l in M9 
and then divided in three flasks, to test different induction OD600nm: 0.6, 0.8 and 1. 
The induction was carried out with 1 mM IPTG for 4 h. The bacteria were harvested 
by centrifugation at 4°C, 10000 rpm, 20 min. The pellet was solubilised in 8 ml of the 
binding buffer (see above) with the protease inhibitors cocktail and lysed by 
sonication (9 s pulse, 9 s pause, for 10 min). The cell debris were removed by 
centrifugation at at 4°C, 14000rpm, 20 min and the final volume reached 16 ml with 
the binding buffer. The sample was loaded in a HisTrap column (GE Healthcare) with 
a peristaltic pump, and then eluted with an AKTA-purifier FPLC system at 150 mM 
imidazole (20 mM NaH2PO4/Na2HPO4, 500 mM NaCl, 10 mM β-mercaptoethanol, 
150 mM imidazole, pH 8). The buffer was exchanged with one with the same 
composition but without imidazole. The cleavage was carried out overnight, with the 
Ulp protease (about 10 units/mg of estimated protein amount), at 4°C, without any 
stirring. The cleaved protein was purified from the SUMO-histag fragment and the Ulp 
protease with a second affinity chromatography. The protein was concentrated and 
the buffer was changed to one suitable for NMR spectroscopy: 32 mM 
KH2PO4/K2HPO4, 50 mM NaCl, 10 mM DTT, 1 mM EDTA, 10% D2O. 
The same expression and purification was performed with the bacterial strain 
Rosetta of Escherichia coli, with induction at OD 0.8. 
 30 
3.2 Cloning of the Saier motif of prestin from Rattus norvegicus 
 
The construct for the expression of the Saier motif of prestin from Rattus 
norvegicus (residues 359-409) was constructed in the ChampionTM pET SUMO 
Protein Expression System by Invitrogen Life Technologies® (figure 7), with the 
SUMO protein at the N-terminal and the kanamicin resistance. The primer set for the 
Saier motif was: forward 5’-AAAACCTTGGCAAATAAGCATGG-3’, reverse 5’-
CTATTACTTCCCTCCAGTTCCTTC-3’., which was amplified from the rat prestin cDNA 
with 30 PCR cycles organized as: 45 s at 95°C, 40 s at 58 °C and 25 s at 72°C, 
preceded by 5 min at 95°C to activate the polymerase only in the first step and 
followed by 20 s at 72°C to add the polyadenilation tails and then 4°C in the end. The 
pET SUMO plasmid was provided already linearized with blunt ends by the supplier 
and the PCR products were ligated with the T4 DNA ligase. 
Bacteria Escherichia coli One shot by Invitrogen Life Technologies® were 
transformed with the ligation reaction by heat shock. The positive clones were 
selected on a plate with Luria Broth agar with 50 g/ml of kanamicin. The plasmids of 
six different positive clones were purified by miniprep (NucleoSpin®) and the correct 
direction of the insertion was checked by agarose gel, after digestion with the 
restriction enzymes Xba and SacI. The only plasmid that gave the two gel bands of 
the expected length was sequenced and found without mutations. The purified 
plasmid was used to transform the bacteria Escherichia coli Mac One by Invitrogen 
Life Technologies® by heat shock. These bacteria are optimized for plasmid 
propagation. The bacteria were cultivated overnight at 37°C, 170 rpm in a 
thermostated orbital shaker and stored in aliquots of 1.2 ml with the 30% of glycerol 
and 50 g/ml of kanamicin in LB at -80°C, preceded by freezing with liquid nitrogen. 
The bacteria Escherichia coli BL21(DE3), suitable for protein expression, were 
transformed with the plasmid of the only positive clone by heat shock, cultivated for 1 
h at 37°C, 200 rpm and then stored at 4°C for immediate cultivation for protein 
expression or -20°C for long term storage. 
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Figure 7: Plasmid map of the ChampionTM pET SUMO Protein Expression System by Invitrogen Life 
Technologies®. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 Expression and purification of the Saier motif of prestin from Rattus norvegicus 
 
A colony from the plate of Escherichia coli BL21(DE3) were cultivate overnight 
in 20 ml of LB. 10 ml of culture were transferred to 500 ml of LB medium and 
incubated at 30°C, 200 rpm, for 4 h. When the bacteria growth reached an optical 
density at 600 nm of 0.6, the protein expression was induced with 1 mM IPTG and 
the culture was transferred at 30°C, to decrease the formation of the inclusion 
bodies. After 6 h, the bacteria were harvested by centrifugation at 4°C, 10 min, 7000 
rpm and the pellet was stored at -20°C. 
The lysis was performed in 20 ml of a affinity chromatography buffer with 10 
mM imidazole, called “binding buffer” (20 mM NaH2PO4/Na2HPO4, 500 mM NaCl, 10 
mM β-mercaptoethanol, 10 mM imidazole, pH7.4) with a cocktail of protease 
inhibitors (mini complete protease inhibitors by Roche®). The bacteria were lysed by 
sonication and the cell debris were spun down by centrifugation, at 4°C, 14000 rpm, 
20 min or by three cycles of French Press. The final volume was doubled with the 
binding buffer and it was loaded slowly with a peristaltic pump in a 1 ml affinity 
column HisTrap (GE Healthcare), functionalized with Nickel-NTA resin. The elution 
was carried out by connecting the column with the AKTA purifier – FPLC system (GE 
Healthcare) and monitored at 280 nm. The protein eluted at 150 mM imidazole (20 
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mM NaH2PO4/Na2HPO4, 500 mM NaCl, 10 mM β-mercaptoethanol, 150 mM 
imidazole, pH7.4), but it  precipitated just after the elution and it was not possible to 
proceed with the purification protocol. The expression and purification were 
attempted twice: in both the cases, the fusion protein precipitated just after the first 
IMAC chromatography.  
 
3.4 Expression and purification of the construct 517-653 of the STAS domain of 
SULTR1;2 from Arabidopsis thaliana 
 
This construct, cloned previously, was expressed at 37°C for 4 h, 170 rpm in 
Minimal Medium M9 with 15NH4Cl in a thermostated shaker. The purification was 
carried out as described for the STAS of prestin, with the AKTA purifier system. 
 
3.5 Cloning of five new constructs of the STAS domain of SULTR1;2 from 
Arabidopsis thaliana 
 
For the STAS domain of SULTR1;2 from Arabidopsis thaliana, 5 constructs 
were designed, as reported in table 2 and 3: 
 
Protein Number of aa Molecular weight (Da) pI 
522-653+SUMO 252 28364.1 5.54 
522-653 133 14966.1 5.11 
525-653+SUMO 249 27975.7 5.54 
525-653 130 14577.7 5.11 
527-653+SUMO 247 27775.5 5.63 
527-653 128 14377.5 5.27 
531-563+SUMO 243 27347.0 5.63 
531-653 124 13949.0 5.27 
525-653+TrxA 264 28948.0 5.31 
525-653+GAM* 132 14750.0 5.11 
 
Table 2: List of the constructs prepared for the STAS domain of SULTR1;2 of Arabidopsis thaliana. 
The features of each construct are reported as fusion protein, followed by the cleaved protein. * The 
construct made in pETM20 is fused with the tioredoxin A (TrxA) and after the cleavage with the TEV 
protease the aminoacids glycine, alanine and methionine (GAM) are left at the N-terminal end of the 
protein. Sequences based on the Uniprot file Q9MAX3 for SULTR1;2. 
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Protein Forward and reverse primers 5’-3’ Tm 
522-653+SUMO 
AGTCAGTATCCTGAAGCCACTA 
TGCTCCAGTAACGCCGGCG 64°C 
525-653+SUMO 
AGCGAAGCCACTATGGTTCC 
TGCTCCAGTAACGCCGGCG 64°C 
527-653+SUMO 
AGTACTATGGTTCCAGGGGTTC 
TGCTCCAGTAACGCCGGCG 66°C 
531-563+SUMO 
AGCGGAGTTCTTACTATTCGTG 
TGCTCCAGTAACGCCGGCG 64°C 
525-653+TrxA 
ACACCATGGAAGCCACTATGGTTCC 
ACACTCGAGTCAGACCTCGTTGGAGA 64°C 
 
Table 3: List of the primers prepared for the STAS domain of SULTR1;2 of Arabidopsis thaliana. 
 
For the four constructs prepared with the SUMO expression system, the 
procedure was the same as described for the cloning of the Saier motif. 
 
The STAS construct 525-653 was prepared also in the pETM20 vector, a non 
patented plasmid provided by the EMBL, Heidelberg, Germany (figure 8). 
 
 
 
Figure 8: Plasmid map of the vector pETM20. 
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The plasmid and the PCR products were digested with the restriction enzymes 
NCoI and XhoI, for 2 h 30 min at 37°C, with 20 min at 65°C in the end to inactivate 
the enzymes. The digested PCR product and plasmid were separated in a gel and 
the correct gel bands were cut and purified with the PureLink® Quick Gel Extraction 
Kit by InvitrogenTM. The plasmid and the PCR product were ligated with the T4 ligase, 
over night at 10°C. The bacteria Escherichia coli Mac One were transformed with the 
ligation reaction by heat shock and plated on LB agar; four colonies were cultivate in 
3 ml of liquid LB, overnight. The plasmids were purified with a miniprep kit and 
digested with the restriction enzymes BamHI and XbaI to verify the correct insertion, 
which generated two fragments of 727 and 5433 bp. The correct clones were 
sequenced and a correct one was used to transform the bacteria Escherichia coli 
Mac One by heat shock. The bacteria were cultivated overnight at 37°C, 170 rpm in a 
thermostated orbital shaker and stored in aliquots of 1.2 ml with 30% of glycerol and 
50 g/ml of kanamicin in LB at -80°C, preceded by freezing with liquid nitrogen. 
For protein expression, the bacteria Escherichia coli BL21(DE3) were 
transformed with the plasmid of the only positive clone by heat shock, cultivated for 1 
h at 37°C, 200 rpm and then stored at 4°C for immediate use or -20°C for long term 
storage. 
 
3.6 Expression and purification of the five new constructs of the STAS domain of 
SULTR1;2 from Arabidopsis thaliana 
 
Preliminary expression trials were performed for each construct, to test two 
different expression temperatures. 100 l of a frozen aliquote of Escherichia coli 
BL21(DE3) transformed with the different plasmids were cultivate in 3 ml of LB 
overnight and then divided and transferred in 100 ml of minimal medim M9 at 37°C, 
180 rpm, for the growth step. Two flasks were prepared for each construct.  At OD 
0.6, the temperature was kept at 37°C for one flask and lowered to 20°C for the other 
flask, and then 1 mM IPTG was added for the induction. A sample of each culture 
was collect every hour, for 4 h. The outcome of the expression trial was checked by 
SDS-PAGE (with 16% gels). 
For the constructs 522-653, 525-653 and 527-653, fused with the SUMO 
protein, and the construct 525-653 in the pETM20 plasmid, the protein expression 
and purification was carried out as described for the STAS domain of Rattus 
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norvegicus, with the AKTA FPLC (GE Healthcare®). The protein expression was 
induced at 0.8 OD, at 25°C, overnight. For the cleavage with the TEV protease of the 
construct 525-635, fused with the Thioredoxin A, the recommended imidazole 
concentration is 150 mM. The NMR buffer was: 32 mM KH2PO4/K2HPO4, 50 mM 
NaCl, 10 mM DTT, 1 mM EDTA, 10% D2O. 
 
The construct 525-653 in pETM20 was further used for the optimization of the  
purification buffer. Two flasks of 1 L of bacterial colture each were prepared. The 
protein expression and lysis were performed as described previously, with the sole 
exception of the induction carried out at 20°C instead of 25°C. The purification was 
carried out with NTA-nickel beads (Qiagen®) in plastic columns and elution for 
gravity, instead of the AKTA FPLC. The product of one liter of bacterial colture was 
purified with the same buffers used for the AKTA FPLC, while for the other liter the 
NaCl in the buffers was completely substituted by 50 mM arginine and 50 mM 
glutammic acid (46). This sample was used to test different NMR buffers. 
1. 50 mM phosphate, 400 mM NaCl, 10 mM DTT, EDTA 1 mM, 0.05% 
NaN3, pH 6.5, 10% D2O 
2. 50 mM phosphate, 50 mM L-Arg, 50 mM L-Glu, 10 mM DTT, EDTA 1 
mM, 0.05% NaN3, pH 6.5, 10% D2O 
3. 50 mM HEPES/NaOH, 50 mM L-Arg, 50 mM L-Glu, 10 mM DTT, EDTA 1 
mM, 0.05% NaN3, pH 7, 10% D2O 
4. 50 mM acetate, 400 mM NaCl, 10 mM DTT, EDTA 1 mM, 0.05% NaN3, 
pH 5, 10% D2O 
5. 50 mM phosphate, 50 mM L-Arg, 50 mM L-Glu, 2% glucose, 10 mM 
DTT, EDTA 1 mM, 0.05% NaN3, pH 6.5, 10% D2O 
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4. RESULTS AND DISCUSSION 
 
4.1 Results of the expression and purification of the STAS domain from prestin of 
Rattus norvegicus 
 
The STAS domain from the rat prestin 505-727 (histag-SUMO-STAS: Mw: 
38002,9; 342 aa; STAS: 24678,0; 223 aa) was first expressed in the Escherichia coli 
strain BL21(DE3). The achieved yield was unsatisfactory (figure 9), while for the 
same construct missing the intervening sequence the yield was good (12). The 
intervening sequence then was supposed to hamper somehow the protein 
expression: excluding that the presence of the sequence itself is badly tolerated or 
degradation-prone by the bacteria, we found that the intervening sequence is rich of 
rare codons (figure 10). This is a problem that generally occurs when an eucaryotic 
protein is expressed in a prokaryote, where the codons usage is different.  
To overcome this problem, we exploited the bacterial strain Rosetta, which is 
optimized for 7 rare codons. Anyway, this was not sufficient to increase the yield to 
achieve a NMR sample (figure 11). 
 
 
 
 
 
 
 
 
 
 
Figure 9: SDS-PAGE, gel15%. E. coli BL21(DE3). Loading order: (1) not induced expression; (2) 1h 
expression; (3) 2h expression; (4) 3h expression; (5) 4h expression; (6) Mw marker (KDa); (7) pellet; 
(8) supernatant; (9); flowthrough of the IMAC loading; (10): protein eluted at 150mM imidazole from 
IMAC 
 
 
1      2      3      4      5      6       7      8       9    10 
97,0 ►
66,0 ►
45,0 ►
30,0 ►
20,1 ►
14,4 ►
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SPSYTVLGQLPDTDVYIDIDAYEEVKEIPGIKIFQINAPIYYANSDLYSSALKRKTGVNPAI
IMGARRKAMRKYAKEVGNANIANATVVKVDAEVDGENATKPEEEDDEVKFPPIVIKTTFPEE
LQRFLPQGENIHTVILDFTQVNFMDSVGVKTLAGIVKEYGDVGIYVYLAGCSAQVVNDLTSN
RFFENPALKELLFHSIHDAVLGSQVREA 
 
agt ccg agc tac aca gtc ctg gga cag ctc cct gac acc gat gta 
tac att gac att gat gcc tat gag gag gtg aaa gaa att cct gga 
ATA aaa ATA ttc caa ATA aat gcc cca att tac tat gca aat agc 
gac ttg tac agc agc gca ctg aaa AGA aag act ggc gtg aac cca 
gca atc atc atg gga gca AGA AGA aag gcc atg AGG aag tac gcg 
aag gag gtt gga aat gcc aac ATA gct aac gcg act gtt gtc aaa 
gtg gat gca gaa gta gat gga gaa aat gct acg aag cct gaa gaa 
gag gac gac gaa gtc aaa ttt CCC cca ATA gtc atc aaa aca aca 
ttt cct gaa gag ctg cag AGG ttt ttg CCC cag ggg gaa aat atc 
cac act gtc att CTA gac ttc acg cag gtc aat ttt atg gat tct 
gtt gga gtg aaa act ctg gct ggg att gtg aaa gag tac ggc gat 
gtt gga att tat gtg tac tta gca gga tgc agt gca caa gtt gtg 
aat gac ctc acc agc aac cgt ttt ttt gaa aat cct gcc tta aag 
gag ctt ctg ttc cac agt atc cat gac gcg gtc ttg ggc agc caa 
gtc cgt gag gcg atg 
 
Red = rare Arg codons AGG, AGA, CGA  
Green = rare Leu codon CTA  
Blue = rare Ile codon ATA  
Orange = rare Pro codon CCC 
 
Figure 10: Rare codons highlighted with different colors in the construct for the STAS of Rattus 
norvegicus with the intervening sequence (underlined). Calculated with: 
http://nihserver.mbi.ucla.edu/RACC/. 
 
 
 
 
 
 
 
 
 
 
Figure 11: SDS-PAGE, gel15%. E. coli BL21 Rosetta.Loading order: (1) not induced expression; (2) 
1h expression; (3) 2h expression; (4) 3h expression; (5) 4h expression; (6) Mw marker (KDa); (7) 
pellet; (8) supernatant; (9); flowthrough of the IMAC loading; (10): protein eluted at 150mM imidazole 
from IMAC. 
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4.2 Result of the expression and purification of the Saier motif 
 
The expression and purification of the Saier motif (histag-SUMO-Saier: 
Mw:18556,8; 168 aa; Saier: 5372,0; 51 aa) was attempted twice. In the first attempt, 
the cellular pellet was lysed by sonication (figure 12). What remained in solution was 
loaded anyway in the IMAC column, but the protein precipitated during the loading. It 
is interesting to note that the fusion protein presented a second band in the SDS-
PAGE, suggesting that it underwent a degradation process. Moreover, the fused 
SUMO protein should have increased the solubility but this did not happen, showing 
a dramatic aggregation during the first chromatographic step of the purification. 
In the second attempt, the bacteria were squeezed with three cycles of French 
Press, which gave a more efficient lysis and most of the protein was in the 
supernatant (figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: SDS-PAGE of the fusion protein Saier-SUMO-histag, first attempt, gel 17%. Loading order: 
(1) Mw marker (KDa); (2) pellet; (3) supernatant; (4) flowthrough; (5) Mw Marker (KDa); (6) elution at 
10 mM imidazole from IMAC; (7) (8) protein eluted at 150mM imidazole from IMAC, two different 
fractions; (9) (10): 300mM imidazole from IMAC, two different fractions. 
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Figure 13: SDS-PAGE the fusion protein Saier-SUMO-histag, second attempt, gel 17%. Loading 
order: (1) Mw marker (KDa); (2) non-induced expression; (3) 1h expression; (4) 2h expression; (5) 3h 
expression; (6) 4h expression; (7) pellet; (8) supernatant; (9) flowthrough (10): protein eluted at 150 
mM imidazole from IMAC 
 
 
 
Anyway, the Saier motif was over expressed but during the purification it had 
serious aggregation problems. Most likely the topological model that we used to 
design the construct Saier motif is not applicable to the prestin of Rattus norvegicus 
and it could be a re-entrant loop or a transmembrane segment in prestin. 
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4.3 Expression and purification of the construct 517-653 of the STAS domain of 
SULTR1;2 from Arabidopsis thaliana 
 
A construct of the STAS of SULTR1.2, previously cloned, encompassing the 
segment 517-653 (histag-SUMO-STAS: Mw: 30497,7; 271 aa; STAS-SULTR1.2: 
17172,7; 152 aa), was expressed for 4 hours, at 37°C in Minimal Medium M9 
supplemented with 15NH4Cl. The expression was not high and a lot of over-
exspressed protein remained in the cellular pellet after the lysis (lane 6, fig.14). We 
continued with the purification of the soluble fraction (lane 7, fig.14). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 SDS-PAGE, gel15%. Loading order: (1) Mw marker (KDa); (2) not induced expression; (3) 
2h expression; (4) 4h expression; (5) (empty); (6) pellet; (7) supernatant; (8) flowthrough of the IMAC 
loading. 
 
After the removal of the histag-SUMO, a process of aggregation started, as 
showed by the asymmetric shape and the long tail of the first two peaks (0 mM 
imidazole), which correspond to the cleaved protein (figure. 15). The SDS-PAGE 
confirmed that the first two peak are composed by the same protein (fig. 16). We tried 
to achieve a NMR sample but the protein appeared strongly aggregated in the HSQC 
experiment (figure 17) and precipitated completely after few minutes in the magnet 
The precipitated protein was clearly visible in the NMR tube. 
1      2      3      4      5      6       7      8
97,0 ►
66,0 ►
45,0 ►
30,0 ►
20,1 ►
14,4 ►
 42 
 
  AffinitaTaglioSTASSULTR210910a:11_UV  AffinitaTaglioSTASSULTR210910a:11_Conc AffinitaTaglioSTASSULTR210910a:11_Fractions
  0
100
200
300
400
mAU
0.0 10.0 20.0 30.0 40.0 ml
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Waste 19 20 Waste 21 22 23 24 25 26 27 28 29 30 Waste
 
 
Figure 15: Chromatogram of the second IMAC purification STAS-SULTR1.2 (after cleavage). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.16: SDS-PAGE, gel 15%. Loading order: (1) protein eluted at 150mM imidazole from the first 
IMAC; (2) Mw marker (KDa); (3) fraction 10mM imidazole from the second IMAC (fraction 3 of fig. 14); 
(4) (5) (6) fractions 10mM imidazole from the second IMAC (fractions 7, 10, 13 respectively, of fig.14); 
(7) fraction 20mM imidazole from the second IMAC (fraction 19 of fig.14); (8) fraction 150mM 
imidazole from the second IMAC (cut protein+SUMO-histag+SUMO protease, fraction 22 of fig. 14).  
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Figure 17: HSQC of the STAS-SULTR1.2 517-653, just after few minutes of the experiment. The 
collapsed signals are due to the aggregation process of the protein. 
 
 
 
4.4 Expression trials of the constructs 525-, 527-, 531-653 of the STAS domain of 
SULTR1;2 from Arabidopsis thaliana 
 
The expression of the new constructs in the SUMO or pETM20 plasmid of the 
STAS domain of SULTR1;2 was tested for 4 h, at 20° and 37°C, in 100 ml of Minimal 
Medium M9. At 37°C, bacteria grow very well but the temperature could be critical for 
protein stability, while at 20° the risk of protein precipitation in the inclusion bodies is 
decreased but the bacterial growth is slowed down: the expression at this 
temperature is consequently run for longer periods, usually overnight.  
The expression showed a dependence on the incubation temperature for what 
concern the SUMO plasmid, since the protein was hardly expressed at 20°C (figure 
18 A, 20 A, 21 A), but copiously at 37°C (figure 18 B, 20 B, 21 B), while for the 
pETM20 a good expression level was achieved also at 20°C (figure 19). The 
following SDS-PAGE gels represent some of the expression trials. 
The construct 522-653 in the SUMO plasmid was included in these trials but 
was tested later.  
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Figure 18: (A) SDS-PAGE of the expression of SUMO-STAS 525 at 20°C, gel 15%. Loading order: 
(1) pellet; (2) supernatant; (3) Mw marker (KDa); (4) 0h expression; (5) 1h expression; (6) 2h 
expression; (7) 3h expression; (8) 4h expression. (B) SDS-PAGE of the expression of SUMO-STAS 
525 at 37°C, gel 15%. Loading order: (1) 0h expression; (2) 1h expression; (3) 2h expression; (4) 3h 
expression; (5) 4h expression. (6) Mw marker (KDa); (7) pellet; (8) supernatant. 
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Figure 19: (A) SDS-PAGE of the expression of pETM20-STAS 525 at 20°C, gel 15%. Loading order: 
(1) Mw marker (KDa); (2) 0h expression; (3) 1h expression; (4) 2h expression; (5) 3h expression; (6) 
4h expression; (7) (empty); (8) Mw marker (KDa); (9) pellet; (10) supernatant (B) SDS-PAGE of the 
expression of pETM20-STAS 525 at 37°C, gel 15%. Loading order: (1) 0h expression; (2) 1h 
expression; (3) 2h expression; (4) 3h expression; (5) 4h expression. (6) Mw marker (KDa); (7) pellet; 
(8) supernatant. 
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Figure 20: (A) SDS-PAGE of the expression of SUMO-STAS 527-653 at 20°C, gel 15%. Loading 
order: (1) Mw marker (KDa); (2) 0h expression; (3) 1h expression; (4) 2h expression; (5) 3h 
expression; (6) 4h expression; (7) (empty); (8) Mw marker (KDa); (9) pellet; (10) supernatant (B) SDS-
PAGE of the expression of SUMO-STAS 527 at 37°C, gel 15%. Loading order: (1) 0h expression; (2) 
1h expression; (3) 2h expression; (4) 3h expression; (5) 4h expression. (6) Mw marker (KDa); (7) 
pellet; (8) supernatant. 
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Figure 21: (A) SDS-PAGE of the expression of SUMO-STAS 531 at 20°C, gel 15%. Loading order: 
(1) Mw marker (KDa); (2) 0h expression; (3) 1h expression; (4) 2h expression; (5) 3h expression; (6) 
4h expression; (7) pellet; (8) supernatant. (B) SDS-PAGE of the expression of SUMO-STAS 531 at 
37°C, gel 15%. Loading order: (1) 0h expression; (2) 1h expression; (3) 2h expression; (4) 3h 
expression; (5) 4h expression. (6) Mw marker (KDa); (7) pellet; (8) supernatant. 
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4.5 Expression and purification of the construct SUMO-STAS 527-653 
 
The construct SUMO-STAS 527-653 was the first one we tried to express and 
purify in larger amount, with a overnight expression at 25°C and purification with the 
FPLC (figure 22 and 23). The cleavage step was critical: we performed it at 4°C, 
under agitation and this was fatal to the protein that clearly underwent precipitation. 
The purification was carried on with the fraction of protein that was still in solution, 
which anyway precipitated soon afterwards (figure 24). It is interesting to note that in 
the SDS-PAGE lanes where the cleaved STAS should be, approximately at the level 
of 14 KDa, there was just a faint band, but there was a big one at 20KDa.  
 
 
 
 
 
 
Figure 22: First affinity chromatography of SUMO-STAS 527-653.  
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Figure 23: Second affinity chromatography of SUMO-STAS 527-653.  
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Figure 24: (A) SDS-PAGE of the expression and purification SUMO-STAS 527-653 at 25°C overnight, 
gel 15%. Loading order: (1) 0h expression; (2) 15h expression; (3) pellet; (4) supernatant; (5) protein 
of interest with histag, pre-cleavage, 150 mM imidazole, first affinity purification, ; (6) flowthrough of 
the IMAC loading; (7) Mw marker (KDa); (8) pellet of the protein of interest, after cleavage with stirring; 
(9) supernatant of the cleavage.(B) SDS-PAGE of the expression and purification SUMO-STAS 527-
653 at 20°C overnight, gel 15%. Loading order: (1) second affinity purification, fraction 5, 10 mM 
imidazole; (2) second affinity purification, fraction 10, 10 mM imidazole; (3) SUMO protease/uncut 
protein, second affinity purification, fraction 23, 150 mM imidazole; (4) Mw marker (KDa); (5) pellet of 
the cleavage( overloaded); (6) fraction 19, second affinity purification; (7) fraction 31, second affinity 
purification. 
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The protein expression was satisfactory but not its stability in solution after the 
removal of SUMO, probably exacerbated by the stirring conditions: for the following 
trials a cleavage with very mild agitation was preferred. 
 
 
4.6 Expression and purification of the construct SUMO-STAS 522-653 
 
The longest of the constructs, SUMO-STAS 522-653, was expressed and 
purified (figure 25, 26 and 27) in the same conditions as the construct starting from 
527, with the exception of the expression temperature set at 20°C and of the 
cleavage, which was carried out at 4°C, overnight, with very mild stirring. As it 
happened for the other SUMO construct, the 527-653, in the SDS-PAGE, in the lanes 
where the STAS protein should be, there was just a light band at about 14 KDa (its 
Mw) and a big one at 20 KDa. 
 
 
 
Figure 25: First affinity chromatography of SUMO-STAS 522-653.  
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Figure 26: Second affinity chromatography of SUMO-STAS 522-653. The spikes on the first part of 
the chromatogram are due to a technical problem (air bubbles in the FPLC). 
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Figure 27: (A) SDS-PAGE of the expression and purification SUMO-STAS 522-653 at 20°C overnight, 
gel 15%. Loading order: (1) 0h expression; (2) 15h expression; (3) pellet; (4) supernatant; (5) Mw 
marker (KDa); (6) protein of interest with histag, pre-cleavage, first affinity purification, fraction 9, 150 
mM imidazole; (7) flowthorough. (B) SDS-PAGE of the expression and purification SUMO-STAS 522-
653 at 20°C overnight, gel 15%. Loading order: (1) Mw marker (KDa); (2) second affinity purification, 
fraction 2, 10 mM imidazole; (3) second affinity purification, fraction 3, 10 mM imidazole; (4) second 
affinity purification, fraction 4, 10 mM; (6) second affinity purification, fraction 6, 10 mM; (7) second 
affinity purification, fraction 7, 10 mM; (8) SUMO protease/uncut protein, second affinity purification, 
fraction10, 150 mM. 
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4.7 Expression and purification of the construct pETM20-STAS 525-653 
 
For its first trial, the construct pETM20-STAS 525-653 was expressed at 25°C 
overnight as usual, and purified with the FPLC (figure 28, 29 and 30). The cleavage 
was carried out under no agitation. 
 
 
 
Figure 28 : First affinity chromatography of pETM20-STAS 525-653.  
 
 
 
Figure 29: Second affinity chromatography of pETM20-STAS 525-653.  
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Figure 30 : SDS-PAGE of the expression and purification of pETM20-STAS 525-653 at 20°C 
overnight, gel 15%. Loading order: (1) 0h expression; (2) 15h expression; (3) pellet; (4) supernatant; 
(5) flowthrough; (6) protein of interest with histag, pre-cleavage, 150 mM imidazole, first affinity 
purification, fraction 78; (7) protein of interest, after cleavage, second affinity purification, fraction 5, 10 
mM imidazole; (8) protein of interest, after cleavage, second affinity purification, fraction 10, 10 mM 
imidazole;.(9) TEV protease/ uncut protein, second affinity, fraction 14, 150 mM imidazole; (10) Mw 
marker (KDa). 
 
 
 
 
A second trial on this construct was attempted to test if the stability could be 
positively influence by a different buffer. Two liters of colture were prepared and the 
protein expression was carried out at 20°C. Both the coltures were purified with just 
nickel NTA beads in plastic columns under gravity , instead of FPLC. One liter of 
colture was purified using the traditional buffers with NaCl (figure 31, A), but the other 
one was purified by using the same buffers with the NaCl substituted by 50 mM Arg 
and 50 mM Glu (figure 31, B) (46). The sample in the buffer with Arg and Glu has a 
better outcome than the one in NaCl. The cleavage with the TEV protease was also 
performed for a total time of 3 day, at 4° and with no stirring, since a overnight 
reaction was not sufficient to cut all the protein. 
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Figure 31: SDS-PAGE of the expression and purification of the construct 525-653 in the vector 
pETM20, gel 15%. (A) Purification performed with traditional buffers with NaCl. (1) Mw marker (KDa); 
(2) 0h expression; (3) 15h expression; (4) pellet; (5) supernatant; (6) protein of interest, after cleavage 
and after the second affinity purification, 0 mM imidazole (7) sample at the end of the cleavage, before 
purification, 150 mM imidazole. (B) Purification with buffers where NaCl was substituted with 50 mM 
Arg and 50 mM Glu (1) 0h expression; (2) 15h expression; (3) pellet; (4) supernatant; (5) Mw marker 
(KDa); (6) protein of interest, after cleavage and after the second affinity purification, 0 mM imidazole 
(7) sample at the end of the cleavage, before purification, 150 mM imidazole. 
 
 
Since the sample was split in five other samples with different buffers, (listed in 
Materials and Methods) the final concentration in each tube was approximately 80 
uM. The samples were first compared as 1D spectra: the buffer n. 5 (50 mM 
phosphate, 50 mM L-Arg, 50 mM L-Glu, 2% glucose, 10 mM DTT, EDTA 1 mM, 
0.05% NaN3, pH 6.5, 10% D20) gave the strongest signal and best signal resolution. 
All the samples tested in the different buffers were all collected in one, concentrated 
and tested in the buffer n. 5 (50 mM phosphate, 50 mM L-Arg, 50 mM L-Glu, 2% 
glucose, 10 mM DTT, EDTA 1 mM, 0.05% NaN3, pH 6.5, 10% D2O) but at a lower pH 
(6.0). One HSQC of this sample was acquired (figure 32). Excluding the signals likely 
due to side chains, the HSQC peaks were approximately 85, out of 126 expected 
(132 amino acids, with 6 prolines). However, at a higher concentration and lower pH, 
the sample gave signs of aggregation and precipitated after 24 hours. 
1       2       3       4       5        6        7
97,0 ►
66,0 ►
45,0 ►
30,0 ►
20,1 ►
14,4 ►
1        2       3       4        5        6        7
97,0 ►
66,0 ►
45,0 ►
30,0 ►
20,1 ►
14,4 ►
 53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: HSQC of the construct pETM20 525-653 of the STAS of SULTR1;2 in the buffer: 50 mM 
phosphate, 50 mM L-Arg, 50 mM L-Glu, 2% glucose, 10 mM DTT, EDTA 1 mM, 0.05% NaN3, pH 6.0, 
10% D2O. Acquired at 600 MHz. 
 

5. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The complete STAS of prestin from Rattus norvegicus, with the IVS 
 
On 2010 the first structure of a mammalian STAS was solved. This was an 
engineered version of the domain, deleted in the intervening sequence, which is the 
most evident difference with the bacterial ASA domains. It is predicted to be 
unstructured and its functional meaning is still obscure, but, since it is highly variable 
among the different proteins, it could be involved in transporter-specific interactions. 
Our aim was to obtain the full STAS of prestin, to complete the structure and to use it 
to investigate the particular interactions of prestin. The first expression and 
purification was attempted in the bacterial strain BL21(DE3) and the outcome was a 
very poor expression of the protein. Since the engineered STAS was expressed in 
abundant amount, the low yield of the full STAS could be evidently explained by the 
presence of the IVS. Unless its presence was destabilizing for the protein by itself, 
the characteristic on the IVS that could hamper its expression was hypothesized to 
be the presence of a large number of rare codons. Luckily, the strain Rosetta of 
Escherichia coli has been optimizied to overcome this problem, but in our case it did 
not change the result of a second expression, giving again a poor yield. 
 
The Saier motif 
 
The structure of prestin and of the SLC26A6 transporters in general is still 
unknown and debated. Consequently, any speculation on their organization in 
transmembrane segments is based on comparison with information about other 
transporters and experimental data. do not allow Solving the structure of 
transmembrane proteins is a very challenging task with the current 
technologies;anyway, extramembrane domains and independent fragments could be 
be isolated and solved separately. This is what we tried to do with the Saier motif, a 
portion of prestin characterized by the presence of the conserved triplet -NQE-. In the 
topological study reported in (45), the Saier motif is suggested to be cytosolic, and 
since some cytosolic portions are known to do interamolecular interaction with C-
terminal domains (9), we wanted to evaluate if the same interaction can occur in 
prestin. The design of the construct was based then on the topology of BicA and it 
 56 
was expressed and partially purified: the protein showed immediately solubility 
problems, since it aggregated even as a fusion protein designed to increase the 
solubility. The presence of a second band in the SDS-PAGE highlighted also 
possible degradation problems. The unsuccessful production of the Saier motif 
suggested that the topological model we used could probably not be applied to 
prestin and that the domain could belong to a transmembrane segment or being a 
loop re-entering in the membrane. The study on the Saier domain was consequently 
postponed to when reliable data about its topology will be available. 
 
The STAS of SULTR1;2 from Arabidopsis thaliana 
 
Most of our efforts was concentrated on getting a sample of the STAS domain 
of the sulfate transporter SULTR1;2 from Arabidopsis thaliana, as a STAS complete 
of IVS and as the first plant STAS. An old construct was tested first, and it 
precipitated. Five new constructs were therefore designed in two different plasmids 
and tested at different expression temperatures. Some of them was also expressed 
and purified in larger amount. We learnt some lessons from all the expression and 
purification attempts and we tried to address the detected problems: 
 No meaningful differences were detected between the constructs, except 
that for an expression of four hours at 20°C the pETM20 construct was 
better than the SUMO. This difference was smoothed over by the 
overnight expression.  
 The best expression temperature was 20°C, overnight: about the 40-50% 
of the protein remained in the pellet, but at 37°C the percentage was much 
higher. The soluble fraction seemed anyway sufficient. 
 The cleavage of the fusion protein under stirring was deleterious, probably 
accelerating the aggregation process: we tried to slow it down by 
eliminating the stirring and lengthening the incubation time. The 
aggregation process was still present but reduced. 
 The soluble fraction seemed enough to reach a NMR sample: we 
preferred to avoid refolding and to focus on optimizing the buffer 
conditions. 
 Since the constructs had the same behavior pretty much but the pETM20 
was more cost effective, we decided to continue with this construct. 
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 During the buffer screening, we notice that the substitution of NaCl with 50 
mM Arg and 50 mM Glu, an expedient often used to increase protein 
solubility at relatively high concentration, helped to achieve a better yield. 
This allowed the achievement of a sample at a concentration suitable for 
NMR experiments and the acquisition of a 15N-HSQC spectrum which 
showed a well dispersion of the peaks. This is indicative of the presence of 
a folded protein. The number of observed signals was anyway significantly 
lower than the expected one and this could be caused to line broadening 
due to conformational exchange in some portion of the protein. 
We planned to screen other buffers, also with detergents, to evaluate if the 
concentration can be raised without compromising the stability and to achieve a 
higher percentage of peaks in the HSQC experiment. 
 

2. INTRODUCTION 
 
6.1 The Myb/SANT domains 
 
The Myb/SANT domains are present in a variety of proteins with different 
functions, from chromatin remodelling enzymes to DNA-binding proteins (47). Their 
most striking characteristic is that, although their functions are heterogeneous, their 
structure is rather conserved: they are constituted by three helices, where the second 
and third helix are displaced in a Helix-Turn-Helix (HTH) motif, of approximately 50 
amino acids (48). Three tryptophans (or other bulky hydrophobic amino acids), 
regularly repeated every 18-19 amino acids and defined as “the tryptophan cluster”, 
contribute to create the hydrophobic core (49) (50) (51) (figure 33, A and B) 
So, since the structure is the same, what makes these domains functionally 
different? A simple answer is in the surface electrostatic properties: in fact, the 
binding surface of these domains is on the third helix and it is positively charged for 
the Myb (52) and negatively for the SANT (47) (53) (figure 33, C). These clearly 
enables them to bind different partners characterized by opposite charge, like DNA or 
histone-tails for the Myb and the SANT respectively: indeed, as an example, the 
name Myb comes from the three tumour suppressor DNA-binding transcription 
factors Myb (A-, B- and c-Myb), while the acronym SANT is derived from four 
histone-interacting enzymes involved in chromatin-remodelling complexes (switching-
defective protein 3 (Swi3), adaptor 2 (Ada2), nuclear receptor co-repressor (NCoR), 
transcription factor IIIB (TF IIIB)) (47). However, the answer to what makes these two 
domains different is more complex, because there is evidence that also the first helix 
can be a binding surface (54).  
A further modulation of the function can be due to accessory structural 
elements, such as additional helices, beta-hairpins or a slight different spatial 
arrangement of the helices. For example, the C-terminal β-hairpin of the Myb3 of 
Thricomonas vaginalis, contributes to the stabilization of the interaction with DNA 
(55), or the R2 repeat of the DNA-binding domain of c-Myb undergoes a 
phenomenon of thermal (56) and conformational instability of its third helix (due to an 
unusual cavity in the hydrophobic core) that is attenuated upon the binding with the 
DNA (57) (58) (59). 
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Not all the Myb bind DNA, such as the single Myb present in the human protein 
Rap1 (60), which binds to hTRF2, a telomeric repeat binding protein (60). 
Interestingly, its Saccharomyces cerevisiae homologue has not lost the DNA-binding 
capability. Other typical Myb with a very weak or non-existent DNA interaction are the 
first repeat of many Myb-like DNA-binding domain, which are organized as multiple 
imperfect Myb repeats (from two to four) (61). In those domains, the DNA-binding 
activity resides in the repeats R2 and R3 (62), while R1 is dispensable, as it occurs in 
many of the Myb proteins in Arabidopsis thaliana, where R1 is not present for most of 
them. 
 
A CB  
 
Figure 33 : (A) the Myb-like DNA-binding domain from hTRF1 (PDB: 1IV6); (B) a R1 domain from the 
mouse protein c-Myb, with the tryptophan cluster in magenta (PDB:1GUU); (C) comparison of the third 
helix of a Myb and a SANT domain, from the point of view of the electrostatic surface (adapted from 
(63)). 
 
 
 
 
 
 
6.2 The cyclin D-interacting Myb-like protein 1(Dmp1) 
 
The cyclin D-interacting Myb-like protein was discovered first in mouse (64) and 
then in human (hDmp1) (65) as phoshorylation substrate by the cyclin D-dependent 
kinases CDK4 and CDK6.  
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hDmp1 exists in three isoforms: the α is the 760 amino acid full-length isoform 
of the protein, with a central DNA binding domain flanked by cyclin D binding sites 
and acidic trans-activating domains. The other two isoforms, β and γ, are truncated 
before the DNA-binding domain (66) (figure 35). Dmp1 does not belong to any gene 
family, but its DNA binding domain is classified as a domain with three Myb-like 
repeats (67). 
The isoform α of Dmp1 is a tumour suppressor transcription factor that exert its 
anti-oncogenic activity controlling the transcription of Arf (68), a pro-apoptotic protein. 
In fact, Dmp1 induces in primary cells an Arf-p53-dependent cell cycle arrest (68) 
(figure 35). hDmp1 recognizes the consensus sequence CCCG(G/T)ATGT (64), 
which can be found not only in the promoter of Arf (68), but also in the promoter of 
CD13/Aminopeptidase N: in this case, the D-type cyclins can hamper the binding 
(69). In fact, cyclins D have the ability to control hDMP1 forming heterodimers and 
they can block its interaction also with CDK4 and DNA (70). Other negative 
regulators of the activity of hDmp1 are: physiological mitogenic stimuli, 
overexpressed E2F (71), genotoxic stimuli by NF-B (72), while the oncogenic Ras 
through the Ras-MEK-ERK signaling (73) and HER2/neu (74) have an indirect 
positive effect (figure 34). The Dmp1 activity can be controlled also by the formation 
of heterodimers of the isoform α, the only one with the DNA-binding domain and the 
tumour suppressor activity, with the isoforms β and γ (66). A wrong control of Dmp1 
activity can lead to pathologies: for example, the isoform β is involved in some forms 
of leukemia, due to splicing aberrations (66), but more frequently and understandably 
is the α isoform mostly involved in cancer. In fact, the deletion of the hDmp1 locus is 
associated with the development of carcinomas (75), such as non-small cell lung 
carcinomas (76) (77) and hematopoietic cancers (75). In Dmp1-null (Dmp1-/-, with 
both the alleles inactivated) mice , with the gene disruption at the Myb-like DNA-
binding domain of Dmp1, it has been observed a development of pulmonary 
adenomas/ adenocarcinomas, vascular tumors, hepatocellular adenomas/ 
adenocarcinomas, B-cell lymphomas and other tumours from the second year of life, 
with the tumorigenesis process accelerated by carcinogens (78). Other less severe 
effects included for example urologic dysfunctions (78). Also the Dmp1+/- mice 
showed a certain propensity to the development of spontaneous cancers, suggesting 
that Dmp1 is haploinsufficient for its anti-oncogenic activity (79). Recently, Dmp1 was 
discovered as a interaction partner of another tumour suppressor, p53, with a 
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positive function in its stability, localization and activity, in an Arf-independent way 
(80). 
mDmp1 exerts an upregulation in genes involved in cell proliferation 
(adrenomedullin), apoptosis (Bcl-3), transcription (JunB, Egr1), DNA methylation 
(methyl-CpG binding domain protein 1), angiogenesis and metastasis 
(thrombospondin-1), and a negative effect on Gas1 and Ect2, which are involved in 
cell cycle and proliferation, as demonstrated in lung tissue of null mice with 
GeneChip Microarrays (81). For some of these genes (amphiregulin, 
thrombospondin-1, JunB and Egr1) a binding of mDMP1 to their promoter has been 
demonstrated (81). 
 
 
 
 
 
 
 
 
 
Figure 34: The three isoforms of hDMP1 (TAD: transactivation domain; CBS: cyclin D binding domain; 
DBD: DNA-binding domain) (66). 
 
 
 
Figure 35: Dmp1 is involed in pathways linking many other tumour suppressors, like Retinoblastome, 
Arf, p53, Ink4a (82). 
TAD TADCBS DBD
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6.3 The Nuclear Receptor CoRepressor 2 (NCoR2) 
 
NCoR2 (Nuclear Receptor Corepressor 2) is a repressor of nuclear receptor 
activity. In the absence of the ligand, the repressor recruits other proteins forming a 
complex that keeps the nuclear receptor in an idle state. In the presence of the ligand 
(a hormone), the repressor complex is removed and the activator complex is formed: 
now the nuclear receptor can dimerize and bind to the “hormone responsive element” 
DNA sequence, starting the transcription (83) (84). 
NCoR2, together with its homologue NCoR1 (also known as SMRT and NCoR 
respectively), are among the most studied repressors (85) (86). They are codified by 
different loci but they share 45% of sequence identity and similar structural 
organization: three or four transcriptional repression domain (RDs) and two or three 
nuclear receptor interaction domain (NRs) depending on the isoforms, respectively at 
the N-terminal and C-terminal end (84) (figure 36). They interact with several 
unligated nuclear receptors: the best known are thyroid hormone receptor T3R (85) 
(86), the retinoid hormone receptor RAR (86), the peroxisome proliferator activated 
receptor PPAR (87), the vitamin D receptor VDR (88); other receptors are reviewed 
in the reference (84). The interaction with the steroid hormone receptors is an 
exception, because it occurs or it is facilitated by the presence of the hormone 
antagonist (89). It is interesting to note that in the disease where the corepressors 
are involved, the pathology is mainly explained by an aberrant corepressor-nuclear 
receptor interaction due to mutation in the receptor, with outcomes ranging from low 
severity diseases to leukemia (90) (91) (92). 
In the binding with the nuclear receptors, the corepressors are assisted by other 
protein components with different roles, like, for example, organizing the chromatin 
condensation (93). For NCoR2, the best known of these partners are: G protein 
pathway suppressor 2 (GPS2) (94), the Transducin-like protein 1 (TBL-1) (95), the 
Transducin-like 1 related protein (TBLR-1) (96) and mSin3 (97). The interaction 
occurs on the surface of the RDs on the corepressor, which is supposed to be mainly 
unstructured, in order to accommodate specific but transient interactions (99). The 
two SANT domains of NCoR2 seem to be among the few structured regions of the 
corepressor (84). Even if they belong to the same family, the functions of these two 
domains are distinct: the N-terminal SANT domain is known also as “Deacetylase 
Activation Domain” (DAD) because it binds and activate the histone deacetylase 3 
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(HDAC) (100), while the other SANT domain is known to be an interaction partner of 
the histone tails of H4, earning the definition of “Histone Interacting Domain” (HID) 
(101). The H4 histone tails are bound only when they are deacetylated, suggesting 
that this SANT domain stabilizes the product rather than the substrate of HDAC3 
(102). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: The two isoforms of NCoR2 (RD: repression domain; ND: nuclear receptor interaction 
domain) (84). 
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6.4 Fast NMR methods for structural proteomics according to the SGC Toronto 
procedures 
 
The mainstream method to solve protein structures by NMR was originally 
developed by Bax et al. (103) (104) (105) (106). This approach can be divided in two 
main steps: the first one consists in determining the sequential assignment with 
13C/15N-experiments based on scalar couplings, while the second one considers the 
information extracted from the NOESY experiments to fold the structure. Some 
drawbacks are associated with this methodology: the experiments sometimes do not 
provide all the scalar connections needed because of sensibility limitations; the 
manual assignment is subjective, prone to inaccuracies and time consuming.; 
increasing the resolution of the spectra means lengthening the experimental time, 
with repercussions on protein stability for delicate samples. To address these issues, 
additional methods have been introduced, like TALOS, a computational approach to 
predict dihedral angle restraints (107); the introduction of the residual dipolar 
couplings (108); experiments with increased dimensionality but with extended 
acquisition time (109) (110) or with less paths of magnetization transfers, for an 
improved sensitivity (105). 
Recently, the introduction of software with a comprehensive approach toward 
the interpretation of data (for instance, with PINE-SPARKY(111)) and the 
development of algorithms for automated structure calculation based on constraints 
extracted from the NOESY experiments (such as CYANA (112)) demonstrated that a 
new inclusive conception of solving protein structure by NMR was coming up. These 
new methods have some drawbacks too, like the fact that any inaccuracies will have 
consequences in the final structure. 
The approach developed at the Structural Genomic Consortium (SGC) in 
Toronto, Canada, is in the frame of this new conception of assignment strategy and 
structure determination and, at the same time, it tries to address some problematic 
issues with new strategies (113). 
The highlights of this method can be listed in four points: 
1. A selection of experiments for assignment and structure calculation 
constituting the minimal dataset. The experiments have been chosen on 
the basis of sensibility, with fewer magnetization transfers and relaxation 
losses compared with the traditional approach. The total acquisition time 
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is reduced but the dataset is self-consistent, providing all the information 
needed for assignment and structure calculation. 
2. A further reduction of the experimental time is achieved by acquiring the 
experiments in a scheme known as Non-Uniform Sampling (NUS) (114). 
NUS is applied with two main purposes: in three-dimensional triple 
resonance experiments, where sensibility is not an issue, it decreases 
the acquisition time by sampling less points following a precise scheme, 
without affecting the resolution; in experiments such as 3D- HCCH-
TOCSY and 13C- and 15N- NOESY, where the spectra can be very 
crowded, the digital resolution is increased without lengthening the 
experimental time. The sparse dataset is restored to a full matrix with the 
Multi Dimensional Decomposition (MDD) algorithm and it is ready to be 
converted in file formats for NMR spectra analysis (as for example 
SPARKY (111),). 
3. The HNCA and the NOESY experiments provide the information needed 
for the sequential assignment. In this way, the NOEs are not just seen as 
constraints for structure calculation but also as a source of information to 
assembly the sequence. This use of the NOESY in an extensive way as 
an assignment tool is a novelty. 
4. All the steps are facilitated by two Graphical User Interfaces (GUI). The 
first GUI is the MDD-GUI, which leads the user to the reconstruction of 
the 3D sparse dataset acquired in NUS modality. The other one is the 
Fragment Monte Carlo-GUI (FMC-GUI) which helps the user in the peak 
lists management, resonance assignment, conversion of input file 
formats for other software and a number of other process, from the 
beginning to the preparation of the files for the final deposition of the 
structures in databases. 
FMC-GUI is not just a management tool: it is integrated with ABACUS (115) 
(113), a procedure of critical importance for the resonance assignment and structure 
calculation in a semi-automated fashion. 
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6.5 The minimal ABACUS dataset: an accurate selection of heteronuclear 2D- and 
3D-NMR experiments 
 
For the determination of the structure of short peptides, the NMR experiments 
based only on the proton frequency and two dimensions (homonuclear experiments) 
can be sufficient to gather all the information required for sequential assignment, 
determination of the secondary structure elements and 3D structure. But if the 
sample presents a higher level of complexity, such as in a protein, the number of 
protons that generates peaks is sensibly larger and the resulting spectra are too 
crowded. This problem can be faced in two ways: using nuclei different from 1H 
(heteronulei) and increasing the number of dimensions in the experiments. 
The choice of the nuclei is related with their presence in the sample under 
investigation and on the abundance of the isotopes with a spin number ½ : for 
example, phosphorus is abundant in nucleic acid and the natural abundance of its 
useful isotope 31P is 100%. For proteins, the useful heteronuclei are 15N and 13C, but 
their natural abundance is just 0.365% and 1.108% respectively: it is anyway 
possible to sensibly enrich a protein sample with the right isotopes just 
supplementing them in the minimal medium where the bacteria expressing the 
protein grow. 
Once obtained a protein sample containing 1H, 15N and 13C, these nuclei are 
exploited for experiments where they can be involved in magnetization transfers. 
Obviously, depending on the experiment, the scales are referred also to the chemical 
shift of the heteronuclei, which are wider than the one of the proton: 100-140 ppm for 
15N and 0-200 ppm for 13C, depending on the experiment. Consequently, the 
possibility of spreading the peaks along larger scales reduces the problem of the 
signal crowding. 
 
The fundamental 2D-heteronuclear NMR experiment for protein is the 
Heteronuclear Single Quantum Coherence (HSQC) (116). As all 2D experiments, it is 
divided in four phases: preparation, evolution, mixing, detection (figure 37). In this 
spectrum, each scalarly coupled 15N and 1H produce a peak: most of them come 
from the backbone, few others, in specific regions of the spectrum, from the side 
chains containing the N-H (figure 38). The magnetization is transferred from 1H to 15N 
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and then back to 1H with the INEPT sequence, to increase the overall sensitivity of 
the experiment, according to the scheme on figure 39 . 
 
 
 
Figure 37: The four sections of a 2D-NMR experiment. 
(from http://www.cryst.bbk.ac.uk/PPS2/projects/schirra/html/2dnmr.htm). 
 
 
 
Figure 38: A typical HSQC spectrum of a protein (http://www.protein-nmr.org.uk/solution-nmr/). 
 69 
 
 
 
Figure 39: Pulse sequence of an HSQC experiment  
(from http://www.chem.queensu.ca/facilities/nmr/nmr/webcourse/hmqc.htm). 
 
Nevertheless, 2D experiments are still not sufficient for the assignment and the 
determination of the protein structure, because of crowding and necessity of finding 
more complex links. A third dimension in then added to a 2D experiment. The 3D 
experiments in addition to reduce signal overlaps can provide different information 
depending on the magnetization transfer and on the coupling (scalar -for chemical 
bonds- or dipolar -for space proximity-) exploited (figure 40 and 41). The main 
drawback associated with these experiments is the long acquisition time that can 
challenge the stability of delicate samples, but methods for decreasing it have been 
developed (such as the Non-Uniform Sampling, NUS). 
 
 
Figure 40: Scheme describing the creation of a 3D NMR experiment (from http://www.bioc.aecom. 
yu.edu/labs/girvlab/nmr/course/COURSE_2012/3DNMR_lecturenotes.pdf). 
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Figure 41: Aspect of a 3D NMR spectrum. The interpretation of the spectrum is based on 2D 
projections (from http://www.bioc.rice.edu/bios576/nmr/nmr.html). 
 
The structural information to fold a protein can be found in the 3D NOESY 
experiments (that retain also sequential information) (figure 42). In these 
experiments, the magnetization is transferred not through the scalar coupling 
(covalent bond) but through the dipolar coupling exploiting the NOE effect, 
generating a signal when the excited atoms are at 5 Å or less of distance. This 
information becomes distance restraints to fold the structure. 
 
  
 
Figure 42: 2D projection of a 
portion of 15N-HSQC-NOESY 
(from http://www.protein-
nmr.org.uk/solution-
nmr/spectrum-descriptions/15n-
noesy-hsqc/). 
 The choice of 2D- and 3D-NMR experiments for proteins is rather wide. For the 
ABACUS dataset, the choice has been made based on the number of magnetization 
transfers and relaxation losses: so, the CBCA(CO)NH and HNCA have been 
preferred toward the less sensitive HNCACB (104), or the HBHA(CO)NH to 
HC(C)CONH. Anyway, new experiments can be added. The dataset can be divided 
in two parts: the first one includes the 15N-rooted experiments and it is called FAWN 
(Fragment Assignment With NOE), while the second one the 13C-edited experiments 
that, together with FAWN, constitutes the full ABACUS dataset (figure 43).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: Definition of the ABACUS dataset and of the magnetization transfers involved in the 
different experiments. (Pictures from http://www.protein-nmr.org.uk/solution-nmr/). 
 
1H-15N HSQC HNCA
HNCO HBHA(CBCACO)NH
CBCA(CO)NH
1H-15N NOESY
1H-13C ct-HSQC H(C)CH TOCSY
(H)CCH TOCSY 1H-13C NOESY
FAWN ABACUS
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6.6 Semi-automated resonance assignment and structure calculation according to 
the ABACUS procedure 
 
The ABACUS procedure (115) is based on BACUS (117), an automated 
Bayesian analysis procedure that achieves protein structures starting from 
unassigned NOESY restraints. It groups many programs with different functions: 
predicting the amino acid type, assembling the sequence, managing the peaklists, 
preparing the format file for other software, etc…(115) (118). All the data needed are 
the primary sequence and the peaklists generated from the manual peak picking of 
the spectra from the minimal dataset: a list of unassigned 1H, 13C and 15N 
resonances divided in Peptide Bond fragments (PB-fragments, figure 44) and 15N- 
and 13C-edited 3D NOESY peak lists. ABACUS do not need the user to label the side 
chains, since it is an operation it performs by itself. It can also generate expected 
peak lists for the NOESY spectra, to help in the analysis, and files in the suitable 
formats for other programs, such as CYANA (112) for structure calculation and CNS 
(119) for refinement. 
 
 
Figure 44: Description of PB-fragment (113). 
 
The starting point consists in determining the amino acid type probability of 
each fragment with the program TYPESYST. This software takes advantage of the 
statistics collected in the BMRB, since the experimental 1H, 13C and 15N resonances 
are strongly dependent on the amino acid type. The following step concerns the 
identification of the NOEs by matching their chemical shifts with the spin system 
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peaks, with BACUS. The NOE links are divided in different categories (COSY peaks, 
TOCSY peaks, intra-residue connectivities, etc…) and the likelihoods of these links 
related with each category are determined with a database of ultra-high resolution x-
ray structures, with a resolution better than 1.0 Å and with a pairwise sequence 
similarity lower than the 25% (118).  
After these two steps, the PB fragments have been created but not sequentially 
connected yet: the two programs; FINDSEQ and FMC, links the fragments (118). 
FINDSEQ creates “clouds of fragments” relying on the Bayesian inference. FMC 
(Fragment Monte Carlo) assembles the fragments trying to reach a minimum in a 
pseudo-energy function, using a thermodynamic analogy. It substitutes the program 
LINKMAP, present in the previous version of ABACUS (115), and it addresses some 
of its issues: the possibility of broadening the positions available to a number bigger 
than the sequence, in order to accommodate the His-Tag, contaminants and the not 
assigned fragments, and a reduced risk of stucking the simulation in a local 
minimum. In the Monte Carlo stochastic sampling, a pseudo-energy profile is 
described for each assignment: the starting point is a “highly energetic” assignment, 
which is modified at every iteration by swapping the fragments in the sequence. Only 
the swaps that are below a certain pseudo-energy level, lower at every iteration, are 
accepted and the simulation can be considered accomplished when the pseudo-
energy profile is not modified anymore. This method is a variation of the Monte Carlo 
method called Multi-Canonical (MUCA). 
A new feature has been included in the latest version of ABACUS (118), to 
obtain a rapid sequence assignment for titrations and relaxation experiments: it is 
called FAWN (Fragment Assignment With NOE) (113). It is an algorithm analogous to 
ABACUS but do not rely on the 13C-rooted experiments, basing its calculations only 
on the peptide fragments excluding the information from the side chains, from the γ 
atoms to the end. Instead, it makes use of the HNCA peak list to sequentially assign 
the fragments, in addition to the NOE information from the 15N–NOESY. 
 
 74 
6.7 Non-Uniform Sampling and Three-Way Decomposition for high-resolution 3D 
NMR spectra 
 
Sampling a high number of points in a FID results in the improvement of the 
resolution, but the price to pay is an increase in the experimental time of the 
spectrum. In particular, in three-dimensional spectra, the time dedicated to the 
indirectly detected dimensions affect sensibly the total acquisition time. The idea that 
the acquisition time can be decreased and the final NMR spectra can be 
reconstructed to a full dataset just based on a selected part of data relies on high 
redundancy of these data: peaks in 3D spectra are about few thousands and can be 
described by a few dozens of numbers each, among the millions of points that are 
collected during a traditional experiment. To override the problem of long 
experimental time while maintaining the resolution, many acquisition schemes and 
reconstruction method have been proposed: an interesting one was elaborated by 
Orekhov et al. (114) and included in the method developed at the SGC Toronto. The 
acquisition method is defined as non-uniform sampling (NUS) and the reconstruction 
scheme is called three-way decomposition (TWD), then implemented in the SGC 
procedure as multidimensional decomposition (MDD). 
This time-saving scheme considers a 3D experiment as a grid of t1- and t2-
values, while the t3-values are acquired just for selected pairs of t1and t2: this data 
set is referred as sparse. The final outcome is reduction of the 70% of the 
experimental time, but the spectral width is preserved and the resolution as well. 
Anyway, the sparsely recorded spectrum is full of grid points without experimental 
data and the FFT algorithm for Fourier transform cannot be applied: the missing 
points are therefore predicted in the time domain and the grid is filled. The resulting 
data set can now be processed as a traditional one, with the standard Fourier 
transform algorithm (figure 45). 
The choice of the combinations of t1- and t2-values is not random in the NUS 
acquisition: it has been demonstrated that sampling at the beginning of the spectra 
yields a higher sensitivity (120). The fundamental requirement of TWD is that no FID 
should be missing for any t1- and t2-value. Signals in data set at least with three 
dimensions can be described by direct products of 1D vectors and the resulting 
decomposition is unique: this is how TWD handles the data. This concept can be 
mathematically described in this way: 
 75 
 
 
2
1
2
1
321min 


M
m
m
M
m
m
k
m
j
m
i
m
ijk
ijkijk aFFFaSG   
 
Where S is the 3D input data set (the experimental time-domain spectrum), 
which can be approximated by 3D components described by the 1D tensor products 
F1, F2, and F3 along the three dimensions. S and F1, F2 and F3 are made of 
discrete points and are a 3D matrix and 1D vectors respectively (63). The aim is 
optimizing the fitting by varying the parameters to minimize the function. The first sum 
over m enumerates the M components, while the second one flattens large 
differences in the size of the components Tikhonov’s factor λ (64) and it is normalized 
by the T; ma  is the amplitude of a component; miF1 , 
m
jF 2  and 
m
kF3  are numbers 
representing the normalized shapes for a component; the indices i, j and k are grid 
points along the three dimensions (65). 
The innovation introduce by Orekhov et al. is the presence of the matrix G , 
where the elements can assume the value 1ijkG  for a recorded and 0ijkG  for a 
skipped data point ijkS in the NMR spectrum. In this way, not recorded spectra will not 
contribute to the penalty function. It is important to point out that S , the input, is 
sparse, but mF1 , mF2  and mF3 , the output, are vectors with complete data: this is 
possible only if S  does not lack an entire plane. By multiplying the shapes mF1 , 
mF2 , mF3  and the amplitudes ma  the full spectrum *S  can be achieved, an optimal 
approximation of the experimental spectrum .S  
The degree of sparsing R is defined by the ratio between the number of (t1, t2) 
combinations used and those in the full spectrum. R is a critical factor, together with 
the number of components M, which can be easily estimated from the number of HN-
H groups in the 15N-1H HSQC spectrum: usually, a sparsing percentage of 30% is 
enough for the reconstruction and it is the percentage used in the ABACUS data set. 
A comparison between NUS/MDD and traditional spectra is reported below (figure 
46). 
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Figure 45: Steps of the NUS protocol. The 3D experiment is acquired as a sparse dataset, which is 
filled with the missing points with the MDD. The fully reconstructed dataset can now be handled as a 
normal one, ready for operations like the Fourier Transform (FT), to generate the final 3D spectrum. 
(Pictures reproduced from http://www.extend-nmr.eu/mdd.htm and http://www.rsc.org/Education/EiC/ 
issues/2008september/ThePowerOfNMRInTwoAndThreeDimensions.asp). 
 
 
 
 
 
Figure 46: Comparison of 13C-edited NOESY spectra obtained with NUS/MDD and fully sampled of 
the protein Atu0922 from Agrobacterium tumefaciens, 121 amino acids, highlighting the difference in 
resolution. The two spectra have been acquired in the same amount of time. (A) Spectrum acquired 
with NUS and processed with MDD, 300 points in the 1H indirect dimension; (B) Spectrum achieved by 
reprocessing the spectrum in (A) but with half the number of indirect complex points with the Fourier 
transform. The arrows indicate peaks that are affected by the resolution. From (113). 
 
FT
7. AIMS 
 
Our aim was determining the structure and characterizing the backbone dynamics of 
two members of the Myb/SANT family. For one of them we perform additional binding 
studies. 
 
The structure of the R1 repeat of the DNA-binding domain of hDMP1 
15N relaxation measurements of R1 
 
The first domain belongs to the protein hDMP1, a tumour suppressor with 
transcriptional activity. Its DNA binding domain can be divided in three Myb-like repeats 
(R1, R2 and R3), where R2 and R3 are the units supposed to interact with the nucleic 
acid. R1 is considered to be accessory, but actually its functions and interactions are still 
unknown. We wanted to solve its structure applying the fast NMR methods developed at 
the SGC Toronto and to analyze its backbone dynamics. 
 
The structure of the SANT2 domain of NCoR2 
Preliminary interaction studies of SANT2 with the H4 histone tails 
15N relaxation measurements of SANT2 
 
NCoR2 presents two SANT domains, defined as DAD (“Deacetylase Activation 
Domain, SANT1) and HID (“Histone Interacting Domain”). The structure of DAD has 
already been solved (63) and we aimed to solve the structure of the HID with the SGC 
Toronto methods and to analyzed its backbone dynamics. Moreover, we planned to start 
preliminary investigations of the binding of SANT2 with the H4 histone tails based on the 
results of Yu et al. (101) and Hartman et al. (102), to map the interaction surface by 
titrations monitored with 1H-15N-HSQC. 
 

8. MATERIALS AND METHODS 
 
8.1 NMR structure determination of the R1 Myb-like repeat of hDmp1 
 
The NMR spectra for structure determination were collected at 298K on Bruker 
Avance 600 and 800 MHz, with cryoprobes. The NMR sample contained 1mM R1 of 
hDMP1 domain and 10 mM sodium phosphate buffer at  pH6.5, 400 mM NaCl, 0.01 mM 
ZnSO4, 10 mM DTT, 1mM benzamidine, 0.01% (v/v) sodium azide, 5% (v/v) D2O.  
The NH-rooted spectra were acquired at 600 MHz (two dimensional 1H-15N HSQC, 
three dimensional CBCA(CO)NH, HNCO, HNCA; HBHA(CO)NH, 1H-15N NOESY), while 
the CH-rooted ones at 800 MHz (the two dimensional 1H-13C constant time HSQC, three 
dimensional, 1H-13C aliphatic NOESY, 1H-13C aromatic NOESY, H(C)CH-TOCSY, 
(H)CCH-TOCSY), with the three dimensional spectra acquired with non-uniform sampling 
(NUS) protocol (121) (114). The two dimensional spectra were processed with NMRPipe 
(107), while the non-uniformly sampled three-dimensional spectra were processed with the 
multidimensional decomposition algorithm of the MDDGUI software (122). Sparky was 
used for the manual peak picking (111); the ABACUS method for the assignment of the 
1H, 15N and 13C resonances (113) and TALOS to calculate the restraints for the backbone 
torsion angle from the chemical shifts (107). Automated NOE assignment and structure 
calculation were performed with CYANA (112). The 20 lowest energy structures were 
refined by restrained molecular dynamic simulation in explicit solvent with the software 
CNS (119). The final structures were inspected with MOLMOL (123) and Pymol (124) and 
evaluated with the PSVS server 1.4 (125). 
 
8.2 Structure deposition of the R1 Myb-like repeat of hDmp1 
 
The structure coordinates and restraints for the R1 repeat of the Myb-like domain of 
hDMP1 have been deposited in the Protein Data Bank under the code 2LLK. The chemical 
shifts have been deposited in the BioMagResBank (University of Wisconsin) with the 
accession no. 18051. 
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8.3 Relaxation measurement of the R1 repeat of the DNA-binding domain of hDmp1 
 
The NMR experiments acquired for analysis of backbone dynamics of the domain 
were conventional experiments based on 2D 1H-15N-HSQC adapted to measuren T1 and 
T2 relaxation times and 15N{1H}-NOE (126), acquired at 600 and 800 MHz, on Bruker 
Avance instruments. The relaxation delay times for T1 were set as follows: 5, 65, 145, 246, 
366, 527, 757, 1148, 1500 ms; CPMG pulse trains of the duration of 34, 51, 68, 85, 102, 
119, 136 ms were used for T2. Two experiments for the measurement of the heteronuclear 
NOE were collected in an interleaved manner at 800 MHz and one at 600 MHz, alternating 
one experiment with proton presaturation with one without it. The recycle delay was 3 s for 
T1 and T2 experiments and 3s of presaturation was used for the heteronuclear NOE 
experiments. 
 
8.4 NMR structure determination of the SANT2 domain of NCoR2 
 
The NMR sample contained 1mM SANT2 domain and 25 mM sodium phosphate 
buffer at pH 6.5, 200 mM NaCl, 10 mM DTT, 1mM benzamidine, 0.01% (v/v) sodium 
azide, 5% (v/v) D2O. The spectra acquisition and processing, the assignment and the 
structure calculation were performed in the same way as reported for the R1 Myb-like 
repeat of hDmp1. 
 
8.5 Structure deposition of the SANT2 domain of NCoR2 
 
The structure coordinates and restraints for the SANT2 domain have been deposited 
in the Protein Data Bank under the code 2LTP. The chemical shifts have been deposited 
in the BioMagResBank (University of Wisconsin) with the accession no. 18492. 
 
8.6 Relaxation measurement of the SANT2 domain of NCoR2 
 
The NMR experiments acquired for analysis of backbone dynamics of the domain 
were conventional experiments based on 2D 1H-15N-HSQC adapted to measure T1 and T2 
relaxation times and 15N{1H}-NOE (126), acquired at 500 and 600 MHz, on Bruker Avance 
instruments. The relaxation delay times for T1 were set as follows: 5, 65, 145, 246, 366, 
527, 757, 1148, 1500 ms; CPMG pulse trains of the duration of 16.33, 32.65, 48.97, 81.61, 
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114.25, 130.57, 163.3 ms at 600 MHz and 16.8, 33.6, 50.4, 67.2, 84, 100.8, 117.6, 134.4, 
151.2, 168 ms at 500 MHz were used for T2. Two experiments for the measurement of the 
heteronuclear NOE were collected in an interleaved manner for each NMR frequency, 
alternating one experiment with proton presaturation with one without it. The recycle delay 
was 3 s for T1 and T2 experiments and 3s of presaturation was used for the heteronuclear 
NOE experiments. 
 
8.7 Expression and purification of the SANT2 domain of NCoR2 for the titration 
experiments 
 
The 15N-labelled SANT2 domain for the titration was expressed with the auto-
induction method, developed by Studier (127). This method exploits the induction of the 
Lac operon by lactose, leading to the protein expression, after a latency time where the 
bacteria grow metabolizing all the glucose in the medium. In fact, Escherichia coli is a 
diauxic bacterium, which means that it can metabolized two kinds of sugars (glucose and 
lactose), but, in presence of both, it prefers glucose because it is ready for its metabolism. 
Moreover, glucose represses the lactose metabolism. In conditions of glucose deprivation , 
the bacterium can metabolize lactose, but it needs to activate the lac operon, which 
constitutes the ensemble of proteins required for lactose metabolism. The stimulation of 
the lac operon leads also to the derepression of the viral T7 polymerase, which starts the 
transcription of the protein of interest in the plasmid. 
This was the composition of the expression medium used for auto-induction protocol: 
25 mM Na2HPO4, 25 mM KH2PO4, 50 mM 15NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 0.2X 
metals (10 µM Fe + other 9 metals), 0.5 % glycerol (54 mM), 0.05% glucose (2.8 mM), 0.2 
% α-lactose (5.6 mM), 0.25% aspartate (18.8 mM), 100 µg/ml kanamicine. 100 µl of 
bacteria from a frozen aliquote were cultivated in 3 ml of LB medium, for 24 h, then 
transferred to 50 ml of auto-induction medium for other 24 h, at 37°C, 170 rpm, in a 
thermostated orbital shaker. The 50 ml of the bacterial colture were added to 450 ml of the 
same auto-induction medium and cultivate for 24 h at 37°C, 170 rpm. The bacteria were 
harvested by centrifugation at 7000 rpm, 4°C, for 20 min. The bacterial pellet, stored at -
80°C, was resuspended 25 ml of lysis buffer (15 mM imidazole, 50 mM Tris, 500 mM 
NaCl, 10 nM ZnSO4) and the cells were lysed by sonication (3 s pulse, 3 s pause, for 5 
min 30 s). The cell debris were removed by centrifugation (at 4°C, 12000 rpm, 25 min). A 
suspension of 3 ml of NTA-Nickel beads (50% beads, 50% buffer) was added to the 
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supernatant in a falcon tube and rocked for 1 h at 4°C. The tube was centrifuged for 5 min 
at 4°C, at 1800 rpm, to spin down the beads. The supernatant was removed, then 12 ml of 
lysis buffer were added and the tube was rocked again. This cycle was repeated twice with 
the lysis buffer with 15 mM imidazole and twice with the one with 30 mM imidazole. After 
the last cycle, without centrifugation, the suspension was loaded on a plastic column for 
gravity elution. The falcon tube was cleaned with 5 ml of the 30 mM imidazole lysis buffer, 
which were loaded in the column too. When the liquid reached the limit of the beads front, 
the elution was carried out with 5 ml of the 500 mM lysis buffer. 1 mM benzamidine and 10 
mM DTT were added. The following day, the buffer was changed with 25 mM Na 
phosphate, 200 mM NaCl, 0.01 mM ZnSO4, 10 mM DTT, 1 mM benzamidine, 0.01% 
NaN3, 5% D2O.  
 
8.8 Preliminary titrations of the SANT2 domain of NCoR2 with a H4 histone tail peptide 
 
The titration of the 15N-labelled SANT2 domain  with the unlabeled H4 was followed 
with 1H-15N HSQC, collected with a Bruker Avance 500 MHz, with a cryogenic microprobe. 
The 24 amino acid H4 histone tail peptide sequence was: 
SGRGKGGKGLGKGGAKRHRKVLRD. 
The amplitude of the chemical shift perturbation was quantified applying the following 
formula: 
 
       21521 154.0 NHNH   
 
The titrations experiments were performed twice, using 40 µl/microtube of 60 µM 15N-
labelled SANT2 domain in the same NMR buffer used to solve the structure. The first time 
the molar ratio of H4 histone tails/SANT2 tested were: 0, 2, 5, 10, 20, 30, 40, 50; the 
second time: 0, 5, 14, 20, 35. 
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9. RESULTS AND DISCUSSION 
 
9.1 Solution structure of the R1 repeat of the DNA-binding domain of hDmp1 
 
The 51 amino acid R1 unit of hDmp1 presented the typical Myb structure. It has 
three α-helices (H1: 228-243; H2: 245-254; H3: 256-267), where the second and the 
last helix form a Helix-Turn-Helix (HTH) motif. In the so called “tryptophan cluster”, 
only a tryptophan is present (W246), the other two are substituted by Y227 and 
C264. The statistics for the NMR structure are reported in table 4, its HSQC in figure 
47 and its structural ensemble in figure 48.  
The surface charge distribution is typical of a Myb domain, as illustrated in 
figure 49: consequently, the SGC Toronto tested the DNA-binding ability of R1, R2-
R3 and R1-R2-R3 toward different DNA sequences (data not reported). As regards 
R1, it did not bind to any of the sequences tested, while the fragment R2-R3 and the 
full domain R1-R2-R3 did bind to most of them. This is in line with the expectations 
about R1 and a possible explanation about its missing DNA-binding capacity can be 
proposed just looking at the amino acid composition of its third helix. Applying a 
reductionist approach, the binding with DNA can be divided in hydrophobic/ 
hydrophilic interactions with the DNA backbone and basis and electrostatic 
interactions with the charged phosphate groups. In the analysis performed by 
Hanaoka et al. (128) about the interaction of the third helix of the Myb domain of 
hTRF1 and hTRF2 with the DNA backbone (sugars and phosphate groups) and 
basis, 16 and 14 amino acids were involved respectively. The comparison with R1 
just in terms of amino acid identity shows that in both the complexes 8 amino acids, 
but different, in the two cases, are conserved (the amino acids written in red in figure 
50). Analyzing the problem in terms of charged amino acids, R1 has a total positive 
charge of +2 in the last helix, while it is +3 for hRAP1, another Myb domain that does 
not bind DNA but proteins, and +4 for hTRF1 and hTRF2, which have almost a helix 
turn more than R1 with two positively charged amino acids (table 5). In conclusion, 
R1 has half of the positive charge and half of the amino acids required for the 
interaction with the backbone compared with known DNA-binding Myb domain, like in 
hTRF1 and hTRF2, explaining its incapacity of interacting with DNA. 
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Table 4: Statistics of the R1 (220-274) NMR structurea. 
 
Conformationally-Restricting Distance Constraints 
Total 733 
Intraresidue [i = j] 155 
Sequential [|i – j| =1] 212 
Medium Range [1< |i – j| <5] 203 
Long Range [|i – j| >5] 163 
NOE constraints per restrained residueb 13.3 
  
Dihedral angle constraints (φ and ψ) 68 
Total number of restricting constraintsb 835 
Total number of restricting constraints per restrained residueb 15.2 
Restricting long-range constraints per restrained residueb 3.0 
Number of structures used 20 
Residual constraints violationsa,c 
NOE distance violations/structure 
0.1-0.2 Å 4.15 
0.2-0.5 Å 0.35 
>0.5 Å 0 
Dihedral Angle Violations/Structure 
1-10° 2.5 
>10° 0 
RMSD Values (Å) 
All residues (backbone atoms) 3.9 
Selected structured (backbone atoms) 0.4 
All residues (heavy atoms) 4.3 
Selected structured (heavy atoms) 1.0 
Structure Quality Factors  
PROCHECK (129) G-factorsd Z score (φ and ψ/all dihedral angles) 1.89/1.24 
PROCHECK (129) G-factorsd mean score (φ and ψ/all dihedral angles) 0.40/0.21 
MOLPROBITY (130) clash score (mean/Z-score) 10.57/-0.29 
R/P/DP scorese 94.6%/94.5%/0.65 
Ramachandran Plot Summary from Procheckf [%] 
Most favored regions 93.7 
Additionally allowed regions 6.3 
Generously allowed regions 0 
Disallowed regions 0 
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a: Analysed for residue 220-274. 
b: There are 55 residues with conformationally restricting constraints 
c: Calculated for all constraints for the given residues, using sum over r^-6 
d: Selected residues: with sum of φ and ψ order parameters > 1.8. Selected residue ranges: 227-242; 
245-266. 
e: Recall: percentage of peaks that are consistent with the structure, they are retrieved by the 
algorithm and are thus part of the query structure; Precision: percentage of expected peaks from the 
structure that are already included in the NOESY peak list; DP score: is a normalized F-measure 
statistic, DP > 0.7 correlates to structures having accuracies of < ~ 2 Å rmsd. 
f: Residue selected based on: Dihedral angle parameter, with S(φ)+S(ψ)>=1.8. Selected residue 
ranges: 227-242; 245-266. 
 
 
 
 
Figure 47: HSQC with the assignment of the R1 repeat of the DNA-binding domain of hDmp1. The 
unassigned peaks correspond to peaks from the histag. 
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Figure 48: Structural ensemble of the R1 Myb-like domain of hDmp1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: (A) R1 Myb of hDmp1; (B) Myb of hRAP1, not DNA-binding; (C) SANT of  NCoR1; histone 
tail binding; (D) Myb of hTRF1, DNA-binding. 
 
 
H3
H2
H1
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Table 5: Comparison of the amino acid composition of the third helix of some DNA-binding and not 
binding Myb domains with the Myb-like repeats of hDMP1. 
 
Myb 
from 
             
Total 
charge 
hTRF1 
Ser 
417 
Val 
418 
Met 
419 
Leu 
420 
Lys 
421 
Asp 
422 
Arg 
423 
Trp 
424 
Arg 
425 
Thr 
426 
Met 
427 
Lys 
428 
Lys 
429 
+4 
hTRF2 
Ala 
484 
Val 
485 
Met 
486 
Ile 
487 
Lys 
488 
Asp 
489 
Arg 
490 
Trp 
491 
Arg 
492 
Thr 
493 
Met 
494 
Lys 
495 
Arg 
496 
+4 
hRAP1 
Trp 
46 
Gln 
47 
Ser 
48 
Leu 
49 
Lys 
50 
Asp 
51 
Arg 
52 
Tyr 
53 
Leu 
54 
Lys 
55 
His 
56 
Leu 
57 
 +3 
hDMP1 
R1 
Ala 
257 
Ser 
258 
Ser 
259 
Val 
260 
Lys 
261 
Asp 
262 
Arg 
263 
Cys 
264 
Arg 
265 
Leu 
266 
Met 
267 
  +2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: Representation of the interaction between hTRF1 or hTRF2 and DNA, with sugars, 
phosphate groups and bases. The not circled amino acids belong to R1 of hDmp1 and especially the 
ones in magenta are the same as hTRF1 or hTRF2. Adapted from (128). 
Leu266
Tyr227
Arg263
Tyr227
Val224
Ser259
Ser258
Ala257
Lys261
Asp262
Arg265
Trp246
Ala247
Leu266
Tyr227
Arg263
Tyr227
Arg221
Ser259
Ser258
Ala257 
Arg265
Lys261
Trp246
Ala247
Ala247
Arg255
Asp262
1
Trp246
Trp246
Hydrophobic contacts Hydrophilic contacts
Contact frequency ~20%  20-70%                   in 20 structures
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9.2 15N relaxation measurement of the R1 repeat of the DNA-binding domain of 
hDmp1 
 
The profile of the relaxation parameters measured for the Myb domain shows 
that the protein is well folded and it does not present any flexible region, besides the 
N- and the C-terminal ends. Five amino acids have been excluded from the analysis 
because of overlaps or bad signal: D220 and H223 in the N-terminal end, D269 and 
C271 in the C-terminal end, all placed in the flexible tails, except for K236. E230 was 
not assigned.Even if the 18 amino acid histag was not removed, being highly flexible, 
this has only a small influence on overall tumbling:   a τc of 4.4 ns, compatible with a 
monomer was measured( monomeric state confirmed by gel filtration 
chromatography).  
Figures 51, 52, 53 and 54 represent respectively the T1, T2, T1/T2 and the 
heteronuclear NOE. 
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Figure 51: T1 of the R1 repeat of the DNA-binding domain of hDmp1. 
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Figure 52: T2 of the R1 repeat of the DNA-binding domain of hDmp1. 
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Figure 53: T1/T2 of the R1 repeat of the DNA-binding domain of hDmp1. 
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Figure 54: Heteronuclear NOE of the R1 repeat of the DNA-binding domain of hDmp1. 
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9.3 Solution structure of the SANT2 domain of NCoR2 
 
The structure is made by four helices, wrapped around an hydrophobic core. 
The statistics for the structures are reported in table 6. The extension of the α-helices 
is: H1 615-631; H2 634-644; H3 647-655; H4 663-682. The C-terminal helix is longer 
and it sticks out from the central core. The loop connecting the third and the last helix 
shows a certain degree of disorder (figure 55). 
During the NMR assignment (figure 56), the presence of a mutation was 
noticed, at position 621, where a glycine substituted a glutammic acid (E261G). 
Anyway, it is likely that such mutation did not affect the backbone structure, since the 
final outcome was in line with what expected, based on secondary structure 
predictions with JPred (131) made with and without the mutation, to check the 
expected length of the helices. The final structures were also compared to other 
SANT three dimensional structures found with the Dali server (132): the N-terminal 
helix, the one affected by the mutation, and the overall structure were apparently not 
perturbed by the mutation. Anyway, this mutation affects obviously the surface 
properties and its repercussion are discussed in the following section about the 
titrations with the H4 histone tails. 
In the hydrophobic core the “tryptophan cluster” (48) (49) (61), typical of the 
Myb domains, is only partially conserved: comparing the SANT2 with the single Myb 
domain of hTRF1 (PDB code: 1ITY), two tryptophans are conserved (W615 and 
W634 in SANT2, corresponding to W383 and W403 for hTRF1) and just one for the 
SANT1 (W432, corresponding to W383 in hTRF1). The tryptophans 403 and 424 in 
hTRF1 are substituted by phenylalanine 451 and tyrosine 470 respectively in the 
SANT1, while in SANT2 tyrosine 653 corresponds to tryptophan 424 of hTRF1. 
The comparison with its cognate domain, the SANT1 (DAD) of NCoR2 (63), 
shows evident differences. The first is the position of the helices: they have both four 
helices, but just the three most C-terminal of the DAD and the three most N-terminal 
of the HID are overlapping with a backbone RMSD of 2.5 Å, excluding the H0 of 
SANT1 and H4 of SANT2 (figure 57).  
A second characteristic that are not shared is a wide hydrophobic groove on the 
surface of the DAD, which is not shared with the HID and generally with the Myb and 
SANT domains (figure 58). This cleft is positioned between the C-terminal half of H3 
and the loop between H1 and H2: the angle between H1 and H3 is approximately 
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118° for the DAD (PDB: 1XC5), 103° for the HID (PDB: 2LTP), 93° and 87° for a Myb 
(PDB: 1ITY) and a SANT (PDB: 2EQR) domain respectively, measured with Pymol 
(124) (figure 59). It has already been demonstrated that this groove belongs partially 
to the interaction/activation surface for the enzyme Histone Deacetylase 3 (HDAC3) 
(63), an interaction that seems to involve just the SANT1 and not the SANT2.  
The analysis of the electrostatic surface revealed the most interesting feature of 
the SANT2 domain: the charge distribution resembles the one of the Myb domains, 
not of the SANT ones. In fact, the third helix has a positive charge, while the first one 
has a negative one (figure 60). If it has DNA-binding properties, currently there are 
no clue about the possible consensus sequence. Some binding tests were performed 
with the same sequences used for the R1 repeat of hDmp1, with negative results 
(data not reported). The histone tail binding properties was also tested and the 
preliminary results are reported in the dedicated section. 
 
 
 
 
Figure 55: Structural ensemble of the SANT2 domain of NCoR2 (PDB: 2LTP). 
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Table 6: Statistics of the SANT2 (615-685) NMR structurea. 
 
Conformationally-Restricting Distance Constraints 
Total 992 
Intraresidue [i = j] 181 
Sequential [|i – j| =1] 279 
Medium Range [1< |i – j| <5] 335 
Long Range [|i – j| >5] 197 
NOE constraints per restrained residueb 15.0 
Dihedral angle constraints (φ and ψ) 107 
Total number of restricting constraintsb 1099 
Total number of restricting constraints per restrained residueb 16.7 
Restricting long-range constraints per restrained residueb 3.0 
Number of structures used 20 
Residual constraints violationsa,c 
NOE distance violations/structure 
0.1-0.2 Å 4.25 
0.2-0.5 Å 0.85 
>0.5 Å 0 
Dihedral Angle Violations/Structure 
1-10° 9.35 
>10° 0 
RMSD Values (Å)  
All residues (backbone atoms) 1.3 
Selected structured (backbone atoms) 0.7 
All residues (heavy atoms) 2.1 
Selected structured (heavy atoms) 1.1 
Structure Quality Factors  
PROCHECK (129) G-factorsd Z score (φ and ψ/all dihedral angles) 1.38/0.65 
PROCHECK (129) G-factorsd mean score (φ and ψ/all dihedral angles) 0.27/0.11 
MOLPROBITY (130) clash score (mean/Z-score) 11.15/-0.39 
R/P/DP scores 94.7%/86.1%/0.733 
Ramachandran Plot Summary from Procheckf [%] 
Most favored regions 93.3 
Additionally allowed regions 6.7 
Generously allowed regions 0 
Disallowed regions 0 
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a: Analysed for residue 615-685. 
b: There are 66 residues with conformationally restricting constraints 
c: Calculated for all constraints for the given residues, using sum over r^-6 
d: Selected residues: with sum of φ and ψ order parameters > 1.8. Selected residue ranges: 615-631; 
634-644; 647-655; 663-682. 
e: Recall: percentage of peaks that are consistent with the structure, they are retrieved by the 
algorithm and are thus part of the query structure; Precision: percentage of expected peaks from the 
structure that are already included in the NOESY peak list; DP score: is a normalized F-measure 
statistic, DP > 0.7 correlates to structures having accuracies of < ~ 2 Å rmsd. 
f: Residue selected based on: Dihedral angle parameter, with S(φ)+S(ψ)>=1.8. Selected residue 
ranges: 615-631; 634-644; 647-655; 663-682. 
 
 
Figure 56: HSQC with the assignment of the SANT2 domain of NCoR2. The not assigned peaks 
correspond to peaks from the histag. 
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Figure 57: Superposition of the DAD domain (magenta, PDB: 1XC5) with the HID domain (yellow, 
PDB: 2LTP). 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: Comparison of the hydrophobic surfaces of the domains, coloured according to the 
Eisenberg’s hydrophobicity scale (133). Top: secondary structure views, oriented in order to show the 
different position of the helix H3. Bottom: surface coloured based on the hydrophobicity; the yellow 
circle highlights the region between H3 and the loop H1-H2. 
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Figure 59: Superposition of a Myb domain (red; PDB: 1ITY), a SANT domain (cyan, PDB: 2EQR), 
DAD (magenta, PDB: 1XC5), HID (yellow, PDB: 2LTP). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60(A) SANT2 of NCoR2; (B) Myb of hTRF1, DNA-binding; (C) SANT of NCoR1; histone tail 
binding. 
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9.4 15N relaxation measurement of the SANT2 domain of NCoR2 
 
The SANT2 of NCoR2 is a 71 amino acid domain with a four helix structure, 
with the long most C-terminal helix protruding from the central core of the protein. 
Three residues were excluded from the analysis, because of overlapping/bad signal 
problems: T616, E617 (both at the N-terminal end of the first helix) and G631. Also in 
this case, the histag was not removed and so the analysis of the relaxation is just 
managed at a qualitative level. During the assignment, eight contiguous amino acids 
were not detected. The analysis of the relaxation data shows high T1/T2 values for 
the amino acids surrounding the disappeared region (figure 63): while the T1 values 
are not anomalous for these amino acids (figure 61), the T2 decrease as they come 
closer to the absent region (figure 62). This is an indication that this segment of the 
domain undergoes a phenomenon of conformational averaging that leads to an 
increasing line broadening, up to the complete disappearance of the peaks. 
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Figure 61: T1 of the SANT2 domain of NCoR2. 
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Figure 62: T2 of the SANT2 domain of NCoR2. 
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Figure 63: T1/T2 of the SANT2 domain of NCoR2. 
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Figure 64: Heteronuclear NOE of the SANT2 domain of NCoR2. 
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9.5 Preliminary binding experiments monitored by 15N-HSQC of the labelled SANT2 
domain with the H4 histone tail peptide 
 
The titrations experiments showed indeed that there is an interaction between 
SANT2 and the histone tails (figure 65). 
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Figure 65: Details of the 15N-HSQC spectra of the titrations, highlighting some of the highest chemical 
shift perturbations. 
 
 
The experiment was repeated twice: the first time the molar ratio of H4 histone 
tails/SANT2 tested were: 0, 2, 5, 10, 20, 30, 40, 50; the second time: 0, 5, 14, 20, 35, 
with the same protein concentration. The two combined titrations experiments of the 
15N-labelled SANT2 with the H4 histone tails show a trend with a double step (figure 
66): this is explained by the presence of a higher concentration of TFA (checked with 
the litmus paper) from the HPLC purification of the peptide from the molar ratio 30 
and on. The lower molar ratios were not sensibly affected by the TFA because the 
concentrated histone tails solution was further diluted to achieve feasible volumes, 
lowering the concentration of TFA. 
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Figure 66: Chart of the two combined titration experiments. 
 
Anyway, the trend seems to reach the saturation before the molar ratio 30, so 
the experiments were analyzed up to the molar ratio 20. The affected amino acids 
belong to the helices 1 and 4 and, in particular, five amino acids have a chemical 
shift perturbation close or higher than 0.1 (figure 67). 
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Figure 67: Chart of the five amino acids with the most significant CSP. 
 
 100 
The area concerned by the major chemical shift perturbations is in close 
proximity to the mutation E621G and since the H4 histone tails are basic (pI 9.1), it is 
not excluded that this missing glutammic acid can be involved in the binding in the 
wild-type protein (figure 68). Moreover, there is a patch of three other glutammic 
acids close to the mutation: the missing glutammic acid could be a “bridge” between 
the area concerned by the titrations and this acid patch on the surface (figure 69). 
 
 
 
 
 
 
 
 
Figure 68: Electrostatic surface of 2LTP (left) and of the wild-type model (right) achieved with HOMER 
(134). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69: (A) Front and (B) back views of the amino acids with a chemical shift perturbation close or 
higher than 0.1 (magenta) in the SANT2 domain; (C) position of the mutation (green) (model achieved 
with HOMER (134)); (D) location of a negative patch of three glutamic acids (yellow). 
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10. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The R1 repeat of hDmp1 
 
The first repeat of hDmp1, a 55 amino acid domain, represented a typical Myb 
domain, with three α-helices where the second and the last one form a Helix-Turn-
Helix. No additional elements are present. The structure was solved with 733 NOE 
based constraints, for an average of 13.3 NOE constraint per residue. 
Since it belongs to a three imperfect Myb repeat DNA binding domain, it was 
tested for its ability to bind known and new sequences and it failed. The explanation 
about its incapacity of interacting with DNA could be found in the comparison with 
other well studied DNA-binding Myb domains: its third helix has approximately half of 
the characteristics necessary to bind the nucleic acid, in terms of charge and 
conservation of residues interacting with the DNA backbone. 
The relaxation analysis did not show any particular feature: the protein did not 
present any disordered region, except for the highly mobile N- and C-terminal ends. 
 
The SANT2 domain of NCoR2 
 
The SANT2 domain of NCoR2 is a 71 amino acid domain that was solved with 
992 NOE based constraints, for an average of 16.6 per residue. Compared with other 
SANT domains, it present an additional C-terminal long helix, protruding from the 
central core. This long helix is connect with the previous one with a loop of 8 
unassigned amino acids that seem to undergo conformational exchange, as 
confirmed by the relaxation analysis. 
The sample used to solve the structure had a mutation that was detected during 
the NMR assignment: this had not a repercussion on the backbone structure but it 
had an effect on the surface charge. In fact, binding experiments with the H4 histone 
tails were performed and monitored with 15N-HSQC with a15N-labelled SANT2 
domain. Five amino acids were found to be affected by the binding and since their 
region is close to the mutation, we planned to repeat the same experiments with the 
wild-type protein. The histone tails in fact are basic and the mutated amino acid is an 
acid one (E621G); in addition, there is a patch constituted by three glutamic acids at 
the N-terminal end of the helix H1: the mutation is in the middle between this patch 
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and the region affected by the binding. If a binding between the H4 histone tails and 
the WT SANT2, on its helix H1, will be confirmed, this will corroborate the fact that 
the SANT2 domain of NCoR2 has to be classified as a Myb domain. Indeed, the 
charge distribution on the different helices on the SANT2 domain was more similar to 
the Myb domains, rather than to the SANT domains. No DNA-binding activity is 
currently known. 
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